Evans blauw als diagnostisch middel voor oppervlakkige blaastumoren: een preklinische studie by Elsen, Sanne
 
 
KU Leuven 
Biomedical Sciences Group 
Department of Pharmaceutical and  
Pharmacological Sciences 
Laboratory for Molecular Biodiscovery  
 
 
 
 
Evans blue as a diagnostic tool for non-muscle-
invasive bladder cancer 
A preclinical study 
 
Sanne Elsen 
 
 
 
 
Jury: 
Promotor:  
Prof. Dr. Peter A. M. de Witte 
Co-promotor:  
Prof. Dr. Hein Van Poppel 
Chair:  
Prof. Dr. Myriam Baes 
Jury members:  
Prof. Dr. Evelyne Lerut 
Prof. Dr. Yicheng Ni 
Prof. Dr. Dirk de Ridder 
Prof. Dr. Juan Palou Redorta 
 
 
Leuven, 2016 
Dissertation presented in partial 
fulfillment of the requirements 
for the degree of Doctor in 
Pharmaceutical Sciences 
   
  
Auditorium Wolfspoort 
Huis Bethlehem 
Schapenstraat 34 
3000 Leuven, Belgium 
 
25 February, 2016 
 
 
 
 
 
 
 
 
 
 
 
Promotor: Professor Dr. Peter de Witte 
Departement Farmaceutische en Farmacologische Wetenschappen 
Laboratorium voor Moleculaire Bio-Ontdekking 
Herestraat 49, O&N II, bus 824 
3000 Leuven 
 
Co-promotor: Professor Dr. Hein Van Poppel 
Faculteit Geneeskunde, Afdeling Urologie 
UZ Herestraat 49, bus 7003 41 
3000 Leuven
   
i 
  
DANKWOORD 
„Every new beginning comes from some other beginning‟s end‟ (Semisonic – Closing time), deze 
zin geeft mooi het gevoel weer waarmee ik dit doctoraat afsluit. De voorbije 4,5 jaren heb ik 
voornamelijk gespendeerd aan dit onderzoek. Vandaag kan ik met een gerust hart deze periode 
afsluiten en tegelijk vooruitkijken naar de toekomst. Er zijn een hele hoop mensen die een 
bedankje verdienen voor de hulp en de mentale steun gedurende de voorbije jaren. 
Allereerst zou ik graag mijn promoter, professor Peter de Witte, willen bedanken. Peter, bedankt 
om mij een plaatsje te geven bij jou in het labo om mijn doctoraat te kunnen verwezenlijken. Ik 
was een beetje de vreemde eend in de bijt tussen al het zebravisonderzoek, maar je hebt steeds je 
best gedaan om ook mijn project goed te begeleiden. Bedankt! Ik zou ook graag mijn co-
promoter, professor Hein Van Poppel, willen bedanken om mij in te leiden in de wereld van de 
urologie. Bedankt om steeds tijd vrij te maken om aanwezig te zijn op mijn presentaties. Ook Drs 
Frank Van der Aa en Ben Van Cleynenbreugel mag ik niet vergeten: bedankt om mij steeds 
verder te helpen met urologie-gerelateerde kwesties en papers na te lezen. 
I would also like to express my grattitude to the members of the jury: professors Myriam Baes, 
Evelyne Lerut, Yicheng Ni, Dirk de Ridder and Juan Palou. Thank you for taking the time to 
read my thesis manuscript and providing valuable suggestions and remarks.  
Uiteraard zijn er ook de collega‟s van het labo voor Moleculaire Bio-Ontdekking die in de 
bloemetjes mogen gezet worden. Ik ben enorm blij dat ik de voorbije jaren in jullie goed 
gezelschap heb mogen doorbrengen. De sfeer in het labo was altijd opperbest en vormde een 
enorme stimulans voor het maken van mijn doctoraat. Hartelijk bedankt daarvoor, zowel de 
„oude‟ generatie labogenoten – Thierry, Evelien, Ann-Sophie, Rik, Lorena, Adriana, Tatiana, 
Olivia, Angela, Mel, Wu, Ibrahim en de masterstudenten – als diegenen die hier nog een tijdje 
zullen blijven: Jan, Daniëlle, Bac, Hung, Yifan, Annelii, Ola, Monika, Chloë, Jo, Niels en Xin-Xin. 
In het bijzonder zou ik volgende collega‟s willen bedanken: 
Daniëlle, mijn allerliefste bureaugenootje, dank je om altijd – zelfs wanneer je zelf verdronk in het 
werk – voor mij klaar te staan. Ik apprecieer je steun en positieve instelling enorm en ik zal je heel 
hard missen op mijn volgende werkplek. Bedankt ook voor de leuke avondjes op restaurant en je 
bezoekjes bij mij thuis! Jan, bedankt voor alle bestellingen, hulp in noodgevallen wanneer een 
toestel het liet afweten en vooral voor je aangename gezelschap! Chloë, bedankt voor de vele 
babbels, zowel over werk als niet-werk gerelateerde zaken. Ik ben blij dat je uiteindelijk toch in 
ons labo bent kunnen blijven want zo heb ik een fantastisch persoon leren kennen! Jo, jij stond 
steeds klaar met een antwoord op farmacologische vragen en natuurlijk ook voor een gezellig 
babbeltje tijdens een thee-pauze. Yifan, thank you for your everlasting kindness. I wish you all the 
best at your wedding day in China. Hung and Bac, thank you for improving my knowledge about 
the Vietnamese culture and for the nice conversations we had. Ola and Annelii, thank you very 
much for the many questions during lab meetings and for your pleasant presence in the lab. Niels, 
ik wens je veel geluk met je doctoraat. Ik weet zeker dat je er een mooi werk van zal maken. 
Bedankt ook om mee de sfeer te creëren tijdens de labo-uitstapjes! Evelien, zowel de eerste jaren 
in het labo als de latere jaren buiten het labo hebben we mooie tijden beleefd. Dank je voor je 
luisterend oor! Ik ben er zeker van dat er nog vele leuke momenten zullen volgen samen ;). 
   
ii 
  
Angela, thank you for the nice talks and moments we shared. I wish you all the best back in 
Hungary and I hope we will still see each other from time to time! 
Ook een welgemeende dankjewel aan de „mensen van het labo hiernaast‟. Bedankt voor de 
babbeltjes in de gang of tijdens de middagpauzes!  
Rita, An H en Chantal, bedankt voor al het logistieke en administratieve geregel! 
Naast mijn collega‟s zijn er nog een heleboel vrienden die ik graag zou willen bedanken. Kathleen, 
wij kennen elkaar al sinds het middelbaar en ondanks het feit dat we eigenlijk maar 2 jaar bij 
elkaar in de klas hebben gezeten, ben je nog steeds een super-vriendin. Ik herinner me met 
plezier onze middelbare schooltijd, de kookavondjes als uniefstudent en de brunches, 
restaurantjes en films sinds we zijn afgestudeerd! Bedankt ook om af en toe op Izzie te 
babysitten. Bastiaan, ik heb je leren kennen tijdens ons 1e jaar Biologie. Ondertussen hebben we 
beiden een heel ander pad bewandeld, ik als doctoraatsstudente, jij als fotograaf. Ondanks het feit 
dat we elkaar ondertussen wat minder zien, ben ik steeds heel blij als ik je kan uithoren over je 
vele avonturen in binnen- en buitenland ;). Bedankt voor de vele, leuke, ontspannende babbels! 
Lise, wij hebben een groot deel van ons doctoraat samen mogen beleven, zij het in ander labo‟s. 
Jij wist als de beste hoe je me kon laten „ontstressen‟. We hebben samen dan ook vele leuke 
momenten meegemaakt, tijdens de spinning, coctail-avondjes, (bier)festivals of gewoon bij ons 
thuis. Super bedankt daarvoor, jij bent ook mijn „schatje-van-patatje‟ ;). Ten slotte zou ik nog 
graag mijn „biologie-vrienden‟ willen bedanken: Inez, Sanne, Karen, Kim, An, Laurine, Michaël en 
Eveline. Bedankt om onze studie Biologie zo plezant te maken! We hebben samen fantastische 
tijden beleefd op bios-td‟s, ecologische uitstappen naar Slapton en Dale of gewoon „op An haar 
kot‟ (want dat was nu eenmaal het grootste  ). Ook nu staan jullie nog steeds voor mij klaar, 
dankjewel daarvoor! Iedereen die nog bezig is met hun doctoraat wens ik veel succes toe! Jawel, 
er komt ooit een einde aan ;). Inez, jou zou ik nog speciaal willen bedanken voor de vele avonden 
die we samen doorbrachten tijdens onze studententijd. Op kot, op café of bij jou in Schelle, het 
was steeds de moeite! 
Moeke en vake, jullie zijn fantastische ouders! Bedankt om me steeds te steunen en me de vrijheid 
te geven om mijn eigen keuzes te maken, maar vooral bedankt om steeds voor een warme thuis 
te zorgen. Hilke en Siebe, ik kan me geen betere, leukere en lievere zus en broer voorstellen dan 
jullie! Bedankt voor de vele mooie tijden die we samen beleefd hebben, zowel toen we nog 
allemaal thuis woonden als nu! Sara, ook jij maakt nu deel uit van de familie en ik ben blij dat ik je 
mijn schoonzusje mag noemen . Ook Anke, Saartje , Jeroen, Mia en Joost wil ik bedanken: jullie 
zijn zoveel meer dan „gewoon‟ familie. Bedankt voor de vele gezellige momenten die we samen 
hebben beleefd en zeker en vast nog zullen beleven! Liefste André, Odrada, Nele, Hanne, Karolien, 
Wim en Katharina. Hartelijk dank om mij vanaf de eerste moment met open armen te ontvangen 
in jullie familie. Bedankt voor alle support! 
Tom en Izzie, jullie zijn ongetwijfeld de 2 allerbelangrijkste personen in mijn leven. Tom, ik had 
nooit gedacht dat een vakantie in Namibië zoveel voor mij in petto zou hebben ;). Ik ben 
supergelukkig dat ik mijn leven samen met jou mag delen. Ik wil je dan ook enorm bedanken 
voor de steun die jij me de voorbije jaren hebt gegeven, op wetenschappelijk maar vooral op niet-
wetenschappelijk vlak. Jij kan telkens weer een glimlach op mijn gezicht toveren en dat maakt mij 
   
iii 
  
de gelukkigste vrouw op aarde! Izzie, je bent een schat van een dochter! Jouw lach en prachtige 
oogjes doen telkens opnieuw mijn hart smelten. Je zal ongetwijfeld een fantastische „grote zus‟ 
worden voor dat kleine wezentje in mijn buik ;)! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
iv 
  
 
  
   
v 
  
TABLE OF CONTENTS 
DANKWOORD………………………………………………………………………………..i 
TABLE OF CONTENTS…………………………………………………………………….v 
LIST OF ABBREVIATIONS……………………………………………………………….vii 
SUMMARY…………………………………………………………………………………....xi 
SAMENVATTING………………………………………………………………………….xiii 
CHAPTER 1: General introduction…………………………………………………………..1 
PART I: Bladder cancer………………………………………………………………………2 
1.1 Structure and function of the normal bladder…………………………………....2 
1.2 Bladder cancer……………………………………………………………….......3 
1.2.1 Incidence………………………………………………………………...3 
1.2.2 Classification of bladder tumors…………………………………………3 
1.2.3 Risk factors……………………………………………………………...5 
1.2.4 Symptoms and diagnosis………………………………………………...7 
1.2.5 Management of bladder cancer………………………………………....11 
PART II: Preclinical models in bladder cancer research…………………………………..13 
2.1       Cell lines in bladder cancer research………………………………………….....13 
2.2 Animal models in bladder cancer research…………………………...…………14 
2.2.1 Orthotopic models……………………………………………………..14 
2.2.2 Heterotopic models…………………………………………………….15 
2.2.3 Genetically engineered models…………………………………………15 
PART III: Evans blue………………………………………………………………………..16 
3.1 Chemical and physical properties………………………………………………………16 
3.2 Clinical use……………………………………………………………………………..17 
AIMS AND OUTLINE OF THE STUDY………………………………………………....19 
CHAPTER II: Biodistribution of Evans blue in an orthotopic AY-27 rat bladder urothelial cell 
carcinoma model: implication for the improved diagnosis of non-muscle-invasive bladder cancer 
(NMIBC) using dye-guided white-light cystoscopy…………………………………………………21 
CHAPTER III: Evans blue-mediated white-light cystoscopy of non-muscle-invasive bladder cancer: 
a preclinical feasibility and safety study using a rat bladder urothelial cell carcinoma model…….……...37 
CHAPTER IV: General discussion and conclusion……………………………………….61 
4.1 Evans blue as a new diagnostic tool for bladder cancer………………………………...62 
4.2 Safety of Evans blue instillations……………………………………………………….64 
4.3 Mechanisms behind the selective accumulation of Evans blue in tumor tissue…………65 
4.4 Translation of our findings into clinical practice………………………………………..68 
4.5 Future perspectives on the use of Evans blue for other bladder diseases...……………..69 
REFERENCES……………………………………………………………………………....71 
CURRICULUM VITAE……………………………………………………………………..81 
   
vi 
  
 
  
   
vii 
  
LIST OF ABBREVIATIONS 
 
5-ALA  5-aminolevulinic acid 
AJ  adherens junction 
BBN  N-butyl-N-(4-hydroxybutyl)nitrosamine 
BC  bladder cancer 
BCFI  Belgisch Centrum voor Farmacotherapeutische Informatie 
BCG  bacillus Calmette-Guérin 
CIS  carcinoma in situ 
DiO  3,3‟-dioctadexyloxacarbocyanine perchlorate 
EAU  European Association of Urology 
EB  Evans blue 
EMT  epithelial-to-mesenchymal transition 
FANT  N-[4-5-nitro-2-furyl-2-thiazolyl]-formamide 
FCS  fetal calf serum 
FDA  Food and Drug Administration 
FDR  false discovery rate 
GAG  glycosaminoglycan  
GEM  genetically engineered mice 
GSTM  glutathione S-transferase 
H&E  hematoxylin and eosin 
HAL  hexaminolevulinate 
HPLC  high-performance liquid chromatography 
IC  interstitial cystitis 
IS  internal standard 
IV  intravenous 
ISUP  International Society of Urological Pathology 
 
 
   
viii 
  
KEGG Kyoto Encyclopedia of Genes and Genomes 
LCM  laser-capture microdissection 
MEM  minimal essential medium 
MIBC  muscle-invasive bladder cancer 
MNU  N-methyl-N-nitrosurea 
NAT  N-acetyltransferase 
NBB  naphtol blue black 
NBI  narrow band imaging 
NMIBC non-muscle-invasive bladder cancer 
NTP  National Toxicology Program 
OCT  optical coherence tomography 
PBS  painful bladder syndrome  
PBS  phosphate buffered saline 
PCA  principal component analysis 
PDD  photodynamic diagnosis 
PpIX  protoporhyrin IX 
PUNLMP papillary urothelial neoplasm of low malignant potential 
PVP  polyvinylpyrrolidone 
PW  pathway 
SCC  squamous cell carcinoma 
SNP  single nucleotide polymorphism 
SPIES  Storz Professional Imaging System 
SV40  simian virus 40 
TCC  transitional cell carcinoma 
TEM  transmission electron microscopy 
TJ  tight junction 
TNM  „Tumor, Node, Metastasis‟ 
   
ix 
  
TUR(B)(T) transurethral resection (of bladder) (tumors) 
UCC  urothelial cell carcinoma 
UICC  Union for International Cancer Control 
UPKII  uroplakin 2 
WHO  World Health Organization 
WL(C)  white-light cystoscopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
x 
  
 
  
   
xi 
  
SUMMARY 
Bladder cancer is a major health problem, with an estimated 429,000 new cases accompanied with 
165,000 deaths in 2012. In the world, bladder cancer is the 4th most common cancer in men and 
the 8th most common malignancy in women. The incidence and prevalence rises with age. At first 
diagnosis, the large majority of detected lesions (70-75 %) are classified as non-muscle-invasive 
bladder cancer (NMIBC) originating from the urothelium. The primary treatment for NMIBC is 
the removal of cancerous tissue from the bladder, called transurethral resection (TUR), used both 
as a diagnostic and therapeutic tool. After a first TUR, most patients (30-80%) experience a 
recurrence of the disease and a variable amount of superficial lesions will eventually progress to 
invasive cancer (1-45% within 5 years). The need to continuously monitor the patients together 
with the expensive treatments, make the cost per patient (from diagnosis to death) the highest 
among all cancers. Therefore, accurate and early diagnosis of NMIBC is essential to offer the 
patients the most appropriate treatment and the highest cure rate, but also to decrease the costs 
associated with this disease.  
White-light (WL) cystoscopy is the gold standard for the visualization of suspicious lesions during 
TUR. In general, this technique works well in the detection of exophytic lesions, but small 
papillary lesions and flat lesions such as carcinoma in situ (CIS) are underdiagnosed. It is believed 
that between 10 and 20 % of tumors are missed with standard equipment. Hence, there is a need 
for better visualization. Recently, the use of fluorescence-guided diagnosis or photodynamic 
diagnosis (PDD) has been implemented in clinical practice. Different studies have indicated that 
PDD improves detection of bladder tumors and reduces recurrence rates up to 1 year. 
Unfortunately, the widespread use and implementation of this technique is hampered by the 
requirement of specific, expensive equipment. The use of a dye that specifically piles up in or 
between tumor cells would be an ideal solution: the advantages of PDD could then be combined 
with the cheaper WL cystoscopy protocol. Our group previously investigated different 
compounds with high absorption coefficients in the visible light spectrum. From this analysis, 
Evans blue (EB) was selected as the only dye showing the desired tumoritropic characteristics as 
revealed with spheroids composed of malignant urothelial cells. It was concluded that the 
compound is a possible promising tool as a clinical diagnostic for bladder cancer. 
Evans blue, also named T-1824 or Direct blue 53, is a water-soluble poly-aromatic diazo dye that 
has a very intense blue color (molar absorption coefficient of 78,100 M-1cm-1 at 626 nm). In this 
study, the tumoritropic characteristics of EB were further investigated using a syngeneic, 
orthotopic AY-27 rat bladder urothelial cell carcinoma model. First, using the fluorescence 
properties of EB, the biodistribution of this compound in the different layers of the bladder wall 
(urothelium, submucosa and muscle) was investigated in healthy and tumor-bearing rat bladders. 
It was concluded that the accumulation of EB in malignant bladders was substantially higher 
compared with healthy bladders, especially in the outer layer of the bladder wall, the urothelium. 
In case of a 1 mM EB instillation for 2 hrs, the EB-associated fluorescence in malignant 
urothelium was 55 times higher as compared to the fluorescence found in normal urothelium. 
Instillations of EB also resulted in some accumulation of the compound in the inner layers of the 
bladder, i.e. the muscle layer. This was observed especially when applying longer instillation times 
(2 hrs). Since the future goal of this research is to apply EB in combination with WL cystoscopy 
without the need for fluorescence imaging, the level of staining of the inner bladder wall after EB 
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instillations was visually inspected. It was clear that tumor-inoculated bladders exhibited a more 
intense blue color as compared to the normal bladders. This observation was confirmed by 
quantitative analysis after a chemical extraction, with a 5.5-fold higher concentration of EB in 
tumor tissue after an instillation of 1 mM for 2 hrs. However, especially for the higher 
concentrations tested, healthy bladder walls also presented with some spots of blue staining, 
possibly due to inflammation or small injuries as a consequence of catheterization. In case of the 
tumor bladders, it was observed that the blue staining was not uniformly spread throughout the 
entire inner bladder wall. This observation could be explained by a non-uniform proliferation of 
the AY-27 tumor cells in the bladder wall or by the local regeneration of normal urothelium at 
the spots with less blue staining. This model-related issue requires further investigation in the 
future.  
To investigate local adverse effects of intravesically instilled EB, this compound was instilled daily 
in healthy rat bladders for up to 7 consecutive days. Histological analysis showed that the 
urothelium was completely intact after exposure to low (1 mM) and high (5 mM) concentrations 
of EB. In some of the rats, slight inflammation and oedema was noticed in the underlying layers, 
e.g. in the lamina propria and muscularis. Since this kind of inflammation was also noticed in the 
control rat bladders in the same extent, we hypothesize that the inflammation was due to the 
repeated instillation procedure and not to adverse effects induced by EB itself.  
Next, to determine the amount of EB that evades from the bladder into the circulatory system, 
EB was extracted from rat plasma. After intravesical instillations, approximately 5 % of the 
amount of EB was able to reach the blood circulation. This observation could raise some safety 
concerns. However, since EB has been frequently used as a dye marker to determine blood 
volume in humans without any adverse reactions, the safety risk for patients after an intravesical 
instillation is considered to be very low. 
Finally, to investigate the mechanisms behind the specific accumulation of EB in tumor tissue, 
cell adhesion between urothelial cells was investigated in different ways. First, transmission 
electron microscopy (TEM) pointed to ultrastructural differences between healthy and malignant 
urothelium. Cells of the healthy urothelium were very tightly interconnected and were 
characterized by the presence of normal cell adhesion junctions, e.g. tight junctions (TJs), 
adherens junctions (AJs) and desmosomes. Conversely, in tumor samples, cells were loosely 
attached to each other and a decreased number of cell junctions were observed. Secondly, 
immunohistochemistry showed that desmoglein-1, an important component of desmosomes, was 
expressed at a lower level in malignant compared with healthy urothelium. E-cadherin, one of the 
building blocks of AJs, was not differentially expressed. Thirdly, transcriptomics of normal and 
malignant urothelium demonstrated that many genes related to cell adhesion were differentially 
expressed, particularly genes coding for proteins involved in TJ formation and regulation. Of 
interest, pathway (PW) analysis of our data set also demonstrated the importance of cell 
adhesion, since the categories „tight junction pathway‟ and „adherens junction pathway‟ were 
significantly enriched. 
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SAMENVATTING 
Blaaskanker is een belangrijk gezondheidsprobleem, met jaarlijks een geschatte 429.000 nieuwe 
gevallen en 165.000 overlijdens ten gevolge van deze ziekte (cijfers gebaseerd op het jaar 2012). 
Globaal gezien is blaaskanker de vierde en achtst meest voorkomende soort kanker in de 
mannelijke en vrouwelijke populatie, respectievelijk. De kans op blaaskanker neemt toe met de 
leeftijd. Bij de initiële diagnose wordt de meerderheid van gedetecteerde letsels (70-75 %) 
geclassificeerd als „niet-spier-invasieve‟ tumors, beperkt tot de dikte van het blaasslijmvlies. 
Initiële therapie voor dit soort tumor is het operatief verwijderen van het maligne weefsel in de 
blaas, een „transurethrale resectie‟ (TUR). Deze operatieve techniek dient zowel voor diagnose als 
voor therapie. Na een eerste TUR ervaren een groot aantal patiënten (30-80 %) een herval. 
Bovendien zullen een aantal lesies uiteindelijk spier-invasief worden (1-45 % binnen de 5 jaar). 
Doordat patiënten frequent moeten worden opgevolgd en de behandelingen duur zijn, zijn de 
kosten geassocieerd met deze ziekte zeer hoog. Meer nog, de kosten van patiënten met 
blaaskanker (van diagnose tot sterfte) worden tot de hoogste gerekend van alle soorten kankers. 
Een correcte en tijdige diagnose van niet-spier-invasieve blaastumors is dus van essentieel belang 
om patiënten de beste behandelingsmogelijkheden en de grootste kans op genezing te bieden, 
maar ook om de kosten van deze ziekte te drukken. 
De dag van vandaag is cystoscopie met wit licht (WL) de algemene standaard voor de visualizatie 
van verdachte lesies tijdens een TUR. In het algemeen is deze aanpak voldoende voor de detectie 
van grote letsels, maar de detectie van kleine papillaire letsels en „carcinoma in situ‟ is dikwijls 
onvoldoende. Met deze standaard techniek worden ongeveer 10 tot 20 % tumors gemist. Deze 
cijfers beklemtonen de noodzaak voor een betere visualizatie tijdens TUR procedures. Recent 
werd het gebruik van fluorescentie cystoscopie of fotodynamische diagnose ingevoerd in de 
klinische praktijk. Verschillende studies hebben aangetoond dat fotodynamische diagnose de 
detectie van blaastumors verbeterd en het aantal recidieven verminderd tot 1 jaar na de ingreep. 
Jammer genoeg is het algemene gebruik van deze techniek beperkt doordat specifiek, duur 
materiaal moet aangekocht worden. Het gebruik van een kleurstof die zich specifiek opstapelt in 
of tussen tumorcellen zou een ideale oplossing zijn: de voordelen van fotodynamische diagnose 
zouden op deze manier gecombineerd kunnen worden met het goedkopere protocol van wit licht 
cystoscopie. In het verleden heeft onze onderzoeksgroep verschillende componenten onderzocht 
met hoge absorptiewaarden in het zichtbare licht spectrum. Door gebruik te maken van sferoïden 
samengesteld uit maligne urotheelcellen, werd aangetoond dat Evans blauw (EB) de enige 
kleurstof was met de juiste tumor-opstapelende eigenschappen. Bijgevolg is deze kleurstof een 
veelbelovend klinisch diagnostich middel voor blaaskanker detectie. 
Evans blauw, ook wel T-1824 of Direct blauw 53 genaamd, is een water-oplosbare poly-
aromatische diazo kleurstof met een zeer intense blauwe kleur (molaire absorptie coëfficiënt van 
78.000 M-1cm-1 bij 626 nm). In dit project werden de tumor-opstapelende eigenschappen van EB 
onderzocht door gebruik te maken van een syngeneïsch, orthotopisch AY-27 rat blaaskanker 
model. Tijdens een eerste experiment werd gebruik gemaakt van de fluorescerende 
eigenschappen van EB om de verdeling in de verschillende lagen van de blaaswand (urotheel, 
blaasslijmvlies en spierlaag) na te gaan in rattenblazen met en zonder blaastumors. Dit experiment 
toonde aan dat de opstapeling van EB in de tumorblazen duidelijk hoger lag vergeleken met 
gezonde blazen, voornamelijk in de buitenste laag van de blaaswand, het urotheel. Een 2 uur-
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durende instillatie van 1 mM EB leidde tot een 55-keer hogere fluorescentiewaarde van EB in 
maligne urotheel in vergelijking met gezond urotheel. Instillaties van EB resulteerden eveneens in 
opstapeling van deze kleurstof in de diepere lagen, d.w.z. in de spierlagen. Dit werd voornamelijk 
gezien in het geval van langere instillatietijden (2 uur). Aangezien het uiteindelijk doel van dit 
onderzoek erin bestaat om EB toe te dienen in combinatie met WL cystoscopie zonder 
fluorescentie-visualizatie, werd de graad van kleuring van de binnenste blaaswand visueel 
onderzocht na EB instillaties. Hieruit bleek dat blazen met tumors een intensere blauwe kleur 
vertoonden dan de normale blazen. Deze visuele observatie werd bevestigd door middel van een 
kwantitatieve analyse na chemische extractie: na een instillatie van 1 mM EB gedurende 2 uur, 
werd een 5,5 keer hogere concentratie waargenomen in tumorweefsel dan in gezond weefsel. 
Voornamelijk bij de hogere concentraties, werden echter ook plekken van blauwe kleuring 
aangetroffen in de gezonde blazen. Dit is waarschijnlijk te wijten aan ontstekingen of kleine 
wondjes ten gevolge van de catheterisatie procedure. In het geval van de tumorblazen werd 
vastgesteld dat de blauwe kleuring niet uniform verspreid was over de gehele binnenste 
blaaswand. Dit kan verklaard worden door een niet-uniforme verdeling van de AY-27 
tumorcellen in de blaaswand of door de lokale regeneratie van normaal urotheel op de plaatsen 
met minder blauwe kleuring. Deze model-gerelateerde kwesties dienen verder onderzocht te 
worden in de toekomst. 
Om lokale ongunstige effecten van intravesicaal geïnstilleerd EB na te gaan, werd deze kleurstof 
dagelijks toegediend in gezonde rattenblazen gedurende 7 opeenvolgende dagen. Histologische 
analyse toonde aan dat het urotheel volledig intact was na blootstellingen aan lage (1 mM) en 
hoge (5 mM) concentraties van EB. In sommige ratten werd een lichte onsteking en oedeem 
waargenomen in de onderliggende lagen, de lamina propria en spierlaag. Aangezien dit soort 
ontsteking in dezelfde mate werd waargenomen in de controle blazen, veronderstellen we dat de 
onstekingen het gevolg waren van de dagelijkse instillatie procedure en niet van negatieve 
effecten geïnduceerd door EB zelf. 
Tevens werd de hoeveelheid EB dat doorsijpelde vanuit de blaas tot in de bloedcirculatie 
onderzocht. Hiertoe werd EB geëxtraheerd vanuit rattenplasma. Dit experiment wees erop dat 
ongeveer 5 % van de oorspronkelijk toegediende EB de bloedcirculatie bereikte. Deze observatie 
zou vragen kunnen oproepen in verband met de veiligheid van EB instillaties. Echter, aangezien 
EB zeer frequent gebruikt werd als merker om het bloedvolume te bepalen in patiënten en er ten 
gevolge van deze toepassing geen ongunstige effecten werden gerapporteerd, kan het 
veiligheidsrisicio voor patiënten na een intravesicale toediening als zeer laag beschouwd worden. 
Als laatste werd het mechanisme achter de specifieke opstapeling van EB in tumorweefsel verder 
onderzocht. Hiervoor werd de celadhesie tussen urotheelcellen nader bekeken op verschillende 
manieren. Ten eerste toonde transmissie elektronen microscopie (TEM) aan dat er 
ultrastructurele verschillen aanwezig waren tussen gezond en maligne urotheel. Cellen van gezond 
weefsel hingen zeer hecht aan elkaar en de aanwezigheid van normale cell adhesie juncties, dit 
zijn de zonula occludens, zonula adherens en de desmosomen, kon duidelijk worden 
waargenomen tussen deze cellen. In tumorstalen daarentegen waren de cellen los met elkaar 
verbonden en celadhesie structuren waren veel minder aanwezig. Ten tweede bleek uit 
immuunhistochemie dat desmogleïne-1, een belangrijk proteïne van de desmosomen, minder tot 
expressie kwam in maligne urotheel vergeleken met gezond urotheel. E-cadherine, een 
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belangrijke bouwsteen van de zonula adherens, werd niet differentieel tot expressie gebracht. Ten 
derde, toonde een transcriptoomanalyse van normaal en maligne urotheel aan dat veel genen 
gerelateerd aan celadhesie differentieel tot expressie werden gebracht. Dit werd voornamelijk 
waargenomen voor  genen die coderen voor zonula occludens vorming en regulatie. Opmerkelijk 
genoeg wees een „pathway‟ (PW) analyse van onze dataset eveneens op het belang van celadhesie, 
aangezien de categorieën „zonula occludens PW‟ en „zonula adherens PW‟ significant verrijkt 
waren. 
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PART I: Bladder cancer 
1.1 Structure and function of the normal bladder 
The urinary bladder is part of the urinary system, also called the renal system. Briefly, urine is 
produced in the kidneys by filtering the blood to excrete waste material and extra water. Urine 
travels through the ureters towards the bladder, which stores the urine until it is eliminated via 
the urethra.  
The bladder is a hollow pear-shaped organ located in the pelvis between the pelvic bones. It is 
not a static structure, but can elastically change its shape according to the amount of collected 
urine. From inside to outside, the bladder wall consists out of four principal layers: the mucosa, 
composed of the urothelium and lamina propria, the submucosa, also known as muscularis 
mucosa, the muscularis (muscle layer) and the serosa (Figure 1.1). 
 
 
Figure 1.1: The human urinary bladder with the different layers of the bladder wall 
(Adopted from Miftahof et al, 2013)  
The multilayered urothelium is the most specialized layer, consisting of three different cell types: 
(1) a cuboid-shaped basal cell layer, (2) an intermediate cell layer and (3) a superficial layer of 
umbrella cells. The umbrella-cell layer is in direct contact with the urine and is covered by a 
protective glycosaminoglycan layer (GAG). The urothelium has different functions: first of all, it 
serves as a barrier against urine constituents, infections, toxins and other irritants. In contrast to 
the old conception, the urothelium is much more than just a passive barrier, as it is also involved 
in some essential functions, like the micturition reflex, metabolic secretion, regulation of 
inflammation and afferent functions (Lazzeri, 2006). Defects in this layer can lead to pathological 
conditions like detrusor overactivity, inflammation, cell growth, differentiation and cancer. 
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1.2 Bladder cancer 
1.2.1 Incidence 
Bladder cancer (BC) is a major health problem worldwide.  It is the 4th most common form of 
cancer in the male population of developed countries, following prostate, lung and colon cancer 
(Jemal et al, 2011). In the US, 74,690 new cases of bladder cancer were recorded accompanied 
with 15,580 deaths in 2014 (Malats & Real, 2015). In the European Union (EU-27), even higher 
numbers were registered in 2008 (110,500 new cases and 38,200 deaths) (Ferlay et al, 2010). A 
change in demographics has been noticed in recent years. In the past, bladder cancer was mainly 
a disease of the western societies, while nowadays more and more cases are arising in developing 
countries due to rising smoking prevalence and exposure to polluted or contaminated water 
sources (Ploeg et al, 2009; Noon & Catto, 2013).  
 
1.2.2 Classification of bladder tumors 
Most bladder cancers (over 90%) are transitional cell carcinomas (TCC), arising from transitional 
cells that line the bladder lumen, 5% of tumors are squamous cell carcinomas and less than 2% 
are adenocarcinomas (Kaufman et al, 2009). Transitional cell carcinomas are also known as 
urothelial cell carcinomas (UCC), the term that should preferentially be used according to the 
World Health Organization/International Society of Urological Pathology (WHO/ISUP) 
(Epstein et al, 1998). 
Roughly, UCCs can be divided into 2 main groups: non-muscle-invasive bladder cancers 
(NMIBC) and muscle-invasive bladder cancers (MIBC). At first diagnosis, approximately 75% of 
detected lesions belong to the NMIBC group (Sharma et al, 2009). These kinds of tumors are 
characterized by low progression rates and patients often have a good long-term prognosis, 
although up to 45% of tumors will eventually progress to invasive tumors (van Rhijn et al, 2009). 
Patients presenting with MIBC have a higher mortality risk (Burger et al, 2013).  
To determine the optimal treatment for the patients, NMIBC and MIBC are further subdivided 
according to the „Tumor, Node, Metastasis‟ (TNM) classification system. This 2002 TNM 
classification system, approved by the Union for International Cancer Control (UICC), has been 
widely accepted and used. In 2009, this version was updated, but no changes for bladder cancer 
determination have taken place (Sobin et al, 2009). The 2009 TNM classification is given in Table 
1.1. 
The TNM system can be explained as follows: The T stands for staging and determines the depth 
of primary tumor invasion into the bladder wall (Figure 1.2): the majority (70%) of NMIBC are 
staged as Ta, which means that the tumors are papillary and confined to the urothelium. 20% of 
NMIBC are T1 tumors, invading the lamina propria, and 10 % are classified as carcinoma in situ 
(CIS), flat lesions confined to the urothelium. Muscle-invasive tumors are staged as T2 (invading 
the muscularis), T3 (infiltrating the perivesical tissue) or T4 (invading other organs). The N 
describes nearby lymph nodes that are possibly involved. There are 4 lymph node stages in 
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bladder cancer (Table 1.1). M stands for metastasis of the primary tumor. There are only 2 
possibilities: either the cancer has spread to distant sites in the body (M1) or not (M0). 
 
Table 1.1: The 2009 TNM classification system for bladder tumors 
 
 
 
 
Figure 1.2: The different stages of bladder tumor invasion 
 
T - Primary tumour
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Ta Non-invasive papillary carcinoma
Tis Carcinoma in situ : 'flat tumor'
T1 Tumor invades subepithelial connective tissue
T2 Tumor invades muscle
T2a Tumor invades superficial muscle (inner half)
T2b Tumor invades deep muscle (outer half)
T3 Tumor invades perivesical tissue:
T3a Microscopically
T3b Macroscopically (extravesical mass)
T4 Tumor invades any of the following: prostate, uterus, vagina, pelvic wall, abdominal wall
T4a Tumor invades prostate, uterus or vagina
T4b Tumor invades pelvic wall or abdominal wall
N - Lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single lymph node in the true pelvis (hypogastric, obturator, external iliac, or presacral)
N2 Metastasis in multiple lymph nodes in the true pelvis (hypogastric, obturator, external iliac, or presacral)
N3 Metastasis in common iliac lymph node(s)
M - Distant metastasis
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis 
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Further characterization of bladder tumors is done by „grading‟, which means that cancer cells are 
classified based on how they look under a microscope. Historically, the 1973 WHO classification, 
subdivided bladder tumors into 3 groups: grade 1 (well differentiated), grade 2 (moderately 
differentiated) and grade 3 (poorly differentiated). This system has been widely used, but the 
definition of the different grades was rather vague and did not take into account the specific 
histological criteria, which resulted in most tumors falling into the intermediate grading group 
(Miyamoto et al, 2010). To avoid this and to obtain a more universal staging system for bladder 
tumors, the WHO/ISUP developed a new classification system in 1998, which was revised in 
2003 (Eble et al, 2004). In this new grading system, papillary urothelial neoplasms are divided into 
4 groups: papilloma, papillary urothelial neoplasm of low malignant potential (PUNLMP), low 
grade papillary carcinoma and high grade papillary carcinoma. Each of these groups is 
accompanied with a detailed description of the architectural and cytological criteria. Among the 
flat lesions, the 2004 system identifies 5 groups: urothelial hyperplasia, reactive urothelial atypia, 
atypia of unknown significance, dysplasia and CIS. There is no one-to-one translation between 
the 1973 and 2004 classification system, as is illustrated in Figure 1.3.  As a consequence, both 
classification systems are still used in the clinic. 
 
 
Figure 1.3: The WHO classification system of 1973 and 2004 compared (Adopted from 
Babjuk et al, 2013) 
 
1.2.3 Risk factors 
 
1.2.3.1 Smoking 
Smoking is considered as the most important risk factor for developing bladder tumors and it is 
estimated to account for 50 % of bladder cancer cases (Freedman et al, 2011). Tobacco smoke 
contains compounds, like aromatic amines, such as β-naphthylamine, and polycyclic aromatic 
hydrocarbons that are known to cause bladder cancer. These compounds are inhaled and 
excreted through the renal system, thereby exposing the bladder wall. The time-frame between 
exposure to smoke compounds and the manifestation of tumors can be more than 30 years 
(Burger et al, 2013). This long latency time makes it difficult to predict the impact of smoking on 
bladder cancer in the future, especially since smoking habits are changing (for example: higher-
educated people are more likely to quit) and the composition of tobacco products has also been 
adjusted over time. Over the years, less tar and nicotine are added but an increase in the 
concentration of β-naphthylamine and tobacco-specific nitrosamines has been found (Hoffmann 
et al, 2001). Several studies have mentioned higher relative risks for lung cancer associated with 
these newly constituted cigarettes (Thun et al,  1997) and a recent article from the New England 
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Bladder Cancer Study suggests that this might also be the case for bladder cancer (Baris et al, 
2009).  
 
1.2.3.2 Occupational exposure 
The second most important risk factor for developing bladder cancer, accounting for an 
estimated 20 % of bladder tumors, is occupational exposure to carcinogens. Dangerous 
compounds in the working environment include aromatic amines, polycyclic aromatic 
hydrocarbons and chlorinated hydrocarbons (Burger et al, 2013). People working in industrial 
settings, processing paint, dye, metal, leather and petroleum products are often exposed to these 
compounds and different studies have indeed shown a higher incidence of bladder cancer in 
employees working in these particular environments (Sorahan et al, 1998; Kogevinas et al, 2003; 
Brown et al, 2012). 
 
1.2.3.3 Gender 
Men are 3-to-4 times more likely to develop bladder carcinomas than women, though women 
usually present with a more advanced form of the disease and have a worse prognosis (Fajkovic 
et al, 2011). No clear explanation for this gender difference has been found, but possible factors 
might be: unequal access to health care, delays in diagnosis and treatment, different exposures to 
carcinogens, anatomic and hormonal factors (sex steroids and receptors). 
 
1.2.3.4 Age 
The risk of developing bladder cancer rises with age. The mean age at diagnosis is approximately 
67 years (Malats & Real, 2015). 
 
1.2.3.5 Schistosoma infection 
While smoking and occupational exposures are the most important risk factors in Western 
countries, chronic infection with the parasitic fluke Schistosoma hematobium causes most cases of 
bladder carcinoma in developing countries, mainly Africa and the Middle East. Schistosomiasis 
causes squamous cell carcinoma (SCC). The exact mechanism of the initiation and progression of 
SCC is not known, but it seems to be a combination of different factors: actions of the parasite, 
host immune response, co-infections, micronutrients and environmental exposure to toxins 
(Honeycutt et al, 2014). Recently, novel sterol-like metabolites and DNA-adducts were found in 
the urine of persons suffering from urogenital schistosomiasis. These reactive molecules are 
metabolized to active quinones that can modify DNA and hence, on the long term, induce 
tumors (Correia da Costa et al, 2014)  
 
1.2.3.6 Genetic predisposition 
Bladder cancer is known to occur more in certain families, though no clear Mendelian inheritance 
pattern can be found. However, some genes have been identified that play a role in de 
development of BC. The enzyme N-acetyltransferase 2 (NAT2), coded by the NAT2 gene, is 
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responsible for the acetylation of aromatic and heterocyclic amine compounds, thereby 
detoxifying several bladder carcinogens. When the NAT2 gene is mutated, the enzyme has a 
decreased capacity to detoxify aromatic amines, thereby increasing the risk to develop bladder 
cancer by 40 % (Garcia-Closas et al, 2005). Another gene related to bladder cancer is the GSTM1 
gene, encoding glutathione S-transferases. These enzymes detoxify several carcinogens, including 
polycyclic aromatic hydrocarbons. GSTM1-null genotypes are at increased risk to develop BC by 
an estimated 50 % (Garcia-Closas et al, 2005). Weak but evident associations with BC were found 
for some DNA repair gene SNPs (single nucleotice polymorphisms), e.g. ERCC2 D312N, NBN 
E185Q and XPC A499V (Stern et al, 2009). 
 
1.2.3.7 Medication and radiation 
Cyclophosphamide, mainly used to treat certain cancers and some life-threatening auto-immune 
diseases, has been associated with an increased risk of BC. Likewise, phenacetin and 
chlornaphazine, two drugs frequently used in the past, are considered as risk factors for bladder 
cancer. These two latter drugs have been withdrawn from the market (Murta-Nascimento et al, 
2007). Radiation therapy to treat cancers in the pelvic region (ovarian, cervical and prostate 
cancers) poses a risk in the development of BC (Murta-Nascimento et al, 2007). 
 
1.2.4 Symptoms and diagnosis 
Most often, the first symptom of bladder cancer is painless blood in the urine, called haematuria. 
Haematuria can be visible in the urine (macroscopic) or not visible (microscopic). Other 
symptoms, more specifically those associated with CIS, are urinary frequency, urgency and 
dysuria. When bladder tumors become more invasive, symptoms like flank, abdominal, pelvic or 
bone pain can occur. 
The first step in the diagnosis of BC is the confirmation of haematuria by microscopic evaluation 
of the urine (urineanalysis). However, the presence of haematuria alone is not very specific for 
bladder cancer, but can also be caused by urinary tract or kidney infections, bladder/kidney 
stones or medications. Therefore, urine cytology is done in which the cells in the urine are 
examined under the microscope. Urine cytology has a high specificity (appr. 94 %), but has a low 
sensitivity, particularly for low-grade bladder carcinoma (25-57 % for low-grade, 53-92 % for 
high-grade bladder carcinoma) (Turco et al, 2011). Negative urine cytology therefore cannot 
exclude BC. 
The “gold standard” for the diagnosis of BC is white-light (WL) cystoscopy. During this 
procedure, a rigid or flexible cystoscope is inserted through the urethra into the bladder to 
thoroughly investigate the bladder wall for tumors. All suspicious lesions are resected (called 
transurethral resection of the bladder or TURB) and investigated by a pathologist. WL 
cystoscopy can be used both as a diagnostic (detecting tumors) and therapeutic (resection of 
tumors) tool. However, this technique has some shortcomings. WL cystoscopy is operator-
dependent, small papillary lesions and CIS are difficult to detect, inflamed and malignant regions 
are difficult to differentiate, margins of tumors are often not clear and grade and stage cannot be 
determined on the spot. These problems can lead to incompletely resected or even missed 
tumors, eventually causing recurrences and progression. After a first TURB, up to 30 to 80 % of 
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patients experience a recurrence of the disease, while a substantial amount of superficial lesions 
will eventually progress to invasive cancer (up to 45% within 5 years) (van Rhijn et al, 2009). To 
avoid this, patients require extensive follow-up, causing BC to have the highest lifetime treatment 
cost per patient of all cancers (Sievert et al, 2009). 
In order to help the surgeon during cystoscopies, new imaging techniques are emerging. 
 
1.2.4.1 Fluorescence cystoscopy/photodynamic diagnosis (PDD) 
By instilling tumoritropic, (pro)-fluorescent compounds inside the bladder before cystoscopy, 
urothelial neoplasms can be visualized more clearly. The mechanism is the following: after 
instillation of the compound, it will selectively accumulate in malignant tissue. During cystoscopy, 
the bladder wall is illuminated with the correct wavelength, causing malignant tissue to emit a red 
fluorescence which makes it more distinguishable from healthy bladder tissue. The first 
compound used was 5-aminolevulinic acid (5-ALA), a precursor of the endogenous 
photosensitizer protoporphyrin IX (PpIX). To improve tissue penetration and to decrease drug 
dose and instillation time, a hexylester of 5-ALA, HAL (hexaminolevulinate; trade name 
Hexvix®/Cysview®) was developed. Other compounds used are hypericin and its derivative 
PVP (polyvinylpyrrolidone) -hypericin which is more water soluble. Hypericin and PVP-hypericin 
are direct photosensitizers, which means they accumulate directly into the tumor tissue.  
HAL instillations were approved by the FDA (Food and Drug Administration) in 2010. The use 
of PDD is recommended by the European Association of Urology (EAU) when CIS or high-
grade tumors are suspected (EAU guidelines, 2015). 
Different studies investigated the efficacy of PDD over WL cystoscopy for NMIBC. A meta-
analysis published in 2013 (Burger et al, 2013) concluded that blue-light cystoscopy with HAL 
improves detection of bladder tumors and reduces recurrence rates up to one year. The odds of 
detecting CIS were 12.4 times higher when using PDD instead of WLC.   
1.2.4.2 Narrow band imaging (NBI) 
Narrow band imaging is a technique in which light of specific blue (415 nm) and green 
wavelengths (540 nm) is used to investigate the bladder wall.  The shorter wavelength penetrates 
the superficial layers of the mucosa; the 540 nm-wavelength penetrates deeper. Since these 
specific wavelengths are absorbed by hemoglobin in the vasculature, tumors, which are often 
highly vascularized, can be more easily detected. The malignant tissue appears as a dark green or 
brown color. Li et al (2013) published a meta-analysis to compare detection rates when NBI was 
used vs. WL cystoscopy. It was reported that an additional 24 % of tumors was detected in an 
additional 17 % of patients. False positive detection rates were similar to those observed with WL 
cystoscopy. Currently, a large international multicenter randomized trial, aiming to investigate 
recurrence rates at 1 year following TURB with white-light vs. TURB with NBI, is being 
conducted (Naito et al, 2013). 
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1.2.4.3 Optical coherence tomography (OCT) 
This technique allows a surgeon to take a non-invasive real-time optical biopsy. Near-infrared 
light (890-1300 nm) is used to capture three-dimensional images of tissues via its scattering 
properties. Since different tissues have different cellular properties, the OCT signal differs for 
each tissue type which makes it possible to distinguish not only the different layers of the bladder 
wall (urothelium, lamina propria, muscularis propria) (Zagaynova et al, 2002) but also benign 
from malignant tissue and even non-invasive tumors (Ta) from invasive tumors (T1-T3) (Goh et 
al, 2008). OCT has several advantages for intravesical diagnostics. OCT can be easily integrated 
with the conventional endoscopes and can be composed with common optical fiber. Also, the 
system is compact and portable. However, before incorporating this technique in clinical practice, 
more in vivo studies/clinical trials should be performed to find out if OCT is able to differentiate 
between low-grade, high-grade and CIS tumors. Also parameters like sensitivity, specificity, and 
positive and negative predictive values need to be established more thoroughly (Bus et al, 2015). 
1.2.4.4 Storz Professional Imaging Enhancement System (SPIES) 
Very recently, a new imaging device has been developed by the Karl Storz company, called Storz 
Professional Imaging Enhancement System. The big advantage of SPIES is that the endoscopic 
view can be monitored in four different ways and two images are projected on the screen, a 
white-light image and an enhanced image (Villa et al, 2015). The four modes of endoscopic 
viewing are the SPECTRA A and B, CLARA and CHROMA mode. With the two SPECTRA 
modes, specific color renderings are projected that enhance local contrasts in the bladder tissue. 
The CLARA mode provides a better visualization of dark regions, while the CHROMA mode 
increases the clearness of anatomical structures. It is believed that by generating clearer images of 
the bladder wall, more tumors are detected and a more complete resection of the detected tumors 
can be performed. Currently, the effectiveness of SPIES vs. WL cystoscopy in NMIBC is 
investigated in a clinical trial (Gravas & Stenzl, 2014). 
1.2.4.5 Urinary biomarkers 
At present, no diagnostic technique is able to replace invasive cystoscopy. Much research has 
been done to look for urinary biomarkers for BC detection. Ideally, a test for surveillance and 
screening for BC needs to be fast, easy to perform, non-invasive and have high sensitivity and 
specificity values. Many markers have been described in literature, but few have been approved 
for clinical use. An overview of some biomarkers under investigation can be found in Table 1.2. 
The main problem with most of these markers is a too low specificity/sensitivity level (see Table 
1.3). To date, no biomarker has been accepted in the guidelines of the EAU (EAU guidelines, 
2015). 
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Table 1.2: Urinary biomarkers for bladder cancer (adopted from Smith & Guzzo, 2013) 
 
 
Table 1.3: Sensitivity and specificity levels of some urinary biomarkers (adopted from 
Smith & Guzzo, 2013) 
 
Recently, an article described the possibility to use a multicomplex biomarker panel for the 
detection of BC. Five highly sensitive and specific biomarkers were combined and tested on urine 
samples of BC patients and patients with benign urological conditions, chronic diseases or other 
cancers. The biomarkers were the following: Corinin-1A, Apolipoprotein A4, Semenogelin-2, γ-
synuclein and DJ-1/PARK7. The combination of these 5 biomarkers lead to higher 
specificity/sensitivity values compared to commercially available tests (Kumar et al, 2015). 
Test (Manufacturer) Marker detected Assay type FDA approval
Cytology Tumor cells Microscopy N/A
BLCA-4 Nuclear matrix protein Sandwich ELISA (rabbit polyclonal -
(Eichrom Technologies) antibody)
BTA stat® Complement factor H-related protein and Immunoassay or point-of-care For diagnosis & follow-up
(Polymedco) complement factor H
BTA TRAK® Complement factor H-related protein and Sandwich ELISA For diagnosis & follow-up
(Polymedco) complement factor H
CYFRA 21-1 Cytoskeletal protein (cytokeratin 19) Immunoradiometric assay or ELISA -
(Bio International; Roche
Diagnostics)
DD23 185-kDa tumor associated antigen Immunocytochemistry -
(UroCor Labs)
NMP22/BladderChek® Nuclear mitotic apparatus protein Sandwich ELISA or point-of-care For diagnosis & follow-up
(Alere)
Survivin Inhibitor of apoptosis gene Bio-dot test (rabbit polyclonal antibody)-
(Fujirebio Diagnostics)
UBCTM cytoskeletal proteins (cytokeratin 8 and 18) Sandwich ELISA or point-of-care -
(IDL Biotech)
ImmunoCyt
TM
/uCyt+
TM Carcinoembryonic antigen, two bladder tumorImmunocytochemistry For follow-up
(Scimedx) cell-associated mucins
UroVysionTM Alterations in chromosomes 3, 7, 17 and 9p21FISH For diagnosis & follow-up
(Abbott, Vysis)
Test
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
Cytology 22-52 96-98 15-55 81-99
BLCA-4 89-96 100 - -
BTA stat® 53-83 67-72 90 76
BTA TRAK® 66-72 51-75 - -
CYFRA 21-1 67-97 67-89 79 89
DD23 70-81 60 - 61-86
NMP22/BladderChek® 47-100 60-90 55-97 29-85
Survivin 64-100 87-93 - -
UBCTM 66-82 83-90 - -
ImmunoCytTM/uCyt+TM 50-100 69-79 - -
UroVysionTM 36-100 89-98 - -
Surveillance Screening
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1.2.5 Management of bladder cancer 
Treatment options for bladder cancer strongly depend on grade and stage of the cancer at initial 
diagnosis. A general scheme can be found in Figure 1.4. 
 
Figure 1.4: Treatment scheme for bladder cancer (adopted from Park et al, 2014) 
 
1.2.5.1 Non-muscle-invasive bladder cancer 
Treatment of NMIBC aims to prevent recurrences and progression, to avoid loss of the urinary 
bladder and to enhance survival of the patients. The standard initial therapy for non-muscle-
invasive bladder cancer consists of a complete transurethral resection of the tumor(s) (TURBT), 
including a part of the underlying muscle. This resection allows pathologists to stage the tumor(s) 
and make decisions about the treatment plan. If necessary (incomplete resection, no muscle in 
specimen), a reresection is performed. Also, in case of T1 and/or grade 3 tumors (with the 
exception of CIS alone), a second TURBT is carried out after 2 to 6 weeks to restage the 
tumor(s). Since non-muscle-invasive bladder tumors have a high tendency for recurrence and/or 
progression after TURBT, intravesical instillation therapy is often recommended. The EAU has 
created guidelines of instillation therapy for NMIBC according to the risk stratification. These 
recommendations are listed in Table 1.4. 
Intravesical instillation is performed with either chemotherapeutic agents or by immunotherapy. 
Mitomycin and thiotepa are often used as chemotherapeutics, while bacillus Calmette-Guérin 
(BCG) is used in immunotherapy. 
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Table 1.4: Treatment recommendations for NMIBC after TURB (adopted from Weijers et 
al, 2015) 
 
 
1.2.5.2 Muscle-invasive bladder cancer 
Standard treatment for MIBC is a radical cystectomy with pelvic lymph node dissection. 
However, the 5-year survival rate after a cystectomy stays low (50-70 % depending on tumor 
stage), despite a 90 % 5-year local control rate (Kaufman, 2006). This observation indicates the 
presence of micrometastases at the time of surgery and requires additional treatments. Different 
studies indicate that neoadjuvant cisplatin-based combination chemotherapy increases the 
survival in patients with MIBC (Grossman et al, 2003; International Collaboration of Trialists, 
2011; Advanced Bladder Cancer Meta-analysis Collaboration, 2003; Winquist et al, 2004). Despite 
the fact that this combination chemotherapy seems to give good outcomes, not all patients are 
good candidates. Excluded are patients that suffer from hearing loss or dysfunction, cardiac 
dysfunction, poor performance status and particularly renal insufficiency (Park et al, 2014). 
Neoadjuvant radiotherapy alone does not give a firm therapeutic benefit (Cole et al, 1995; 
Crawford et al, 1987). Adjuvant chemotherapy is recommended for patients at high risk for 
recurrence. 
As an alternative to radical cystectomy, different bladder-sparing strategies have been developed. 
These can be surgical (TURBT, partial cystectomy) or non-surgical (radiation, chemotherapy). 
Single treatment options, however, are often suboptimal. Therefore a trimodal strategy with the 
combined power of surgery, radiation and chemotherapy has been tested in clinical trials and 
shows promising outcomes (Rödel et al, 2002; Kaufman et al, 2000; Elmunt et al, 2012). 
 
 
Risk category Definition Treatment Recommendation
Low Primary, solitary, Ta, G1 (low grade), 
<3 cm, no CIS
One immediate instillation of 
chemotherapy
Intermediate All cases not defined in the 2 
adjacent categories
One immediate instillation of 
chemotherapy followed by further 
instillations, either chemotherapy for 
a maximum of 1 y or 1 y full-dose BCG
High Any of the following: Full-dose BCG instillations for 1-3 y 
• T1 or cystectomy (in highest risk tumors)
• G3 (high grade)
• CIS
• Multiple and recurrent and large 
(>3 cm) TaG1-2 tumors (all conditions 
must be presented)
Abbreviations : BCG, bacillus Calmette-Guérin; TaG, tumor stage "a" grade
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PART II: Preclinical models in bladder cancer research 
2.1 Cell lines in bladder cancer research 
“Normal urothelial cell lines” are cell lines originating from healthy urothelium, which can be 
used as a control in bladder cancer research. These cell lines have been established by a variety of 
methods including organ cultures (Knowles et al, 1983; Scriven et al, 1997), primary cultures (de 
Boer et al, 1996), subcultured cell lines and urothelial cell-stroma recombinants (Scriven et al, 
1997). 
Bladder cancer cell lines are usually derived from immortalized cell lines, since primary cultures 
are difficult to obtain and often fail in culture over time. Especially low-grade superficial bladder 
cancers, the majority of newly diagnosed cases, are difficult to establish in culture (Seifert et al, 
2007). Therefore, most human TCC cell lines are derived from high-grade, poorly differentiated 
cancers, which can be seen in table 1.5. 
Table 1.5: Overview of commonly used cell lines in bladder cancer research (adopted from 
Gabriel et al, 2007) 
 
Most studies on cell lines are performed on cells grown in monolayers. This technique is easy and 
cost-effective, but has several limitations, the most important one being the fact that they do not 
mimic the in vivo situation very well. A solution is 3D cell culture, which is gradually becoming 
more and more applied by laboratories in the world. In 3D cell culture, cells are allowed to grow 
as spheroids (cell colonies that grow in 3 dimensions) by different techniques. The general idea 
behind the generation of spheroids is to minimize interactions between cells and substrate and to 
maximize cell-cell interactions. Common techniques include: hanging drop method, liquid overlay 
cultures, continuous spinning techniques and scaffolding techniques. 3D cell culture has many 
advantages compared with 2D cell culture. The multicellular aggregates show similar 
characteristics as the 3D original tissue mass, like their histoarchitecture, nutrient gradients, 
oxygen levels, proliferation rate, pH, response to stimuli, cell-cell communication etc. (Antoni et 
al, 2015). Also, very importantly, the genotype displayed by 3D spheroids is significantly more 
relevant to the in vivo situation compared to 2D cultures (Smith et al, 2012). A more practical 
advantage is that cells grow in 3D can be cultured up to 4 weeks versus only 1 week for 
monolayer cultures due to confluency. 
Cell line Origin of biopsy Clinical stage of disease Established in Gender
5637 Primary TCC n.a. 1974 Male
BC-3C Invasive, solid TCC G4, C 1998 Female
CAL-29 Invasive, metastatic TCC G4, T2 1985 Female
HT-1376 Invasive TCC T2, G3 1977 Female
HT-1197 Recurrent invasive TCC T2, G4 1977 Male
KU-19-19 Invasive TCC pT3b, G3 1993 Male
RT4 Recurrent TCC G1, T2 1968 Male
RT112/84 Primary TCC G2 1973 Female
T24 Primary TCC G3 1970 Female
U-BLC1 Primary TCC spontaneously immortal min. pT2, G3 1998 Female
UM-UC 3 TCC n.a. 1982 Male
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2.2 Animal models in bladder cancer research 
Animal models are an essential step in the final preclinical testing procedure before continuing to 
clinical trials. To increase the chances of a drug working in humans, animal models must 
resemble the human situation. In rodents, the lower urinary tract shows a remarkable structural 
and functional similarity to that of humans (Oyasu, 1995). Also, induced bladder neoplasms in 
rodents are histologically similar to the human disease and even share similar genetic pathways 
during the development of the tumors (Williams et al, 2008). In the next section, different animal 
models of bladder cancer will be reviewed. 
2.2.1 Orthotopic models 
In an orthotopic model, the cancer will grow at the normal place in the body, in our case in the 
bladder.  
2.2.1.1 Spontaneous models 
Spontaneous development of bladder tumors in rodents is a rare event, but is very common in 
dogs, affecting tens of thousands of dogs each year worldwide (Fulkerson & Knapp, 2015). Dogs 
most often suffer from invasive urothelial carcinoma, which closely resembles invasive TCC in 
humans and therefore might form an opportunity to investigate this disease and translate its 
findings to the human situation. Dogs are often used to study genetic and environmental risk 
factors for the development of TCC, but also to test new therapies (Knapp et al, 2014). One 
example of a promising new therapy for bladder cancer is folate-targeted therapy. It has been 
shown that certain cancers have a high uptake of folate (vitamin B9) and folate drug conjugates 
due to an up-regulation of folate receptor (FR) expression. Clinical trials are ongoing to test 
folate-targeted therapy in humans with ovarian and lung cancer. The potential value of this 
therapy for bladder cancer was tested in a dog study with promising results (Dhawan et al, 2013). 
2.2.1.2 Chemically induced models 
Exposure to chemical carcinogens (like aromatic amines, polycyclic aromatic hydrocarbons and 
chlorinated hydrocarbons) is an important risk factor for the development of bladder cancer in 
humans and this is also the case in rodents. Therefore, by exposing them to carcinogens under 
the appropriate conditions, bladder tumors can be generated. Most agents used to induce BC in 
rodents have aromatic amine components, like FANT (N-[4-5-nitro-2-furyl-2-thiazolyl]-
formamide), BBN (N-butyl-N-(4-hydroxybutyl)nitrosamine) and MNU (N-methyl-N-nitrosurea). 
These carcinogens are usually administered orally to the animals, but injections, intravesical 
instillations or other methods are also possible. 
BBN is the most popular agent to be used due to its lack of systemic toxicity and the exclusive 
development of urothelial carcinoma (Bertram et al, 1972). The carcinogen is added orally, either 
by gavage or added to the drinking water, in concentrations of 0.01 to 0.05% for a period of 16 
to 30 weeks. Nearly 100% of animals fed with BBN display bladder tumors after treatment (Wu 
et al, 2000). Importantly, the treatment generates different kind of tumors in mice versus rats: in 
mice, the formed tumors are often muscle-invasive and metastatic, while in rats the tumors are 
mostly low-grade, papillary and non-muscle-invasive (DeGraff et al, 2012). Formed tumors are 
genetically and pathologically similar to the human disease.  
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2.2.1.3 Orthotopic xenograft and syngeneic models 
In orthotopic xenograft models, human urothelial cancer cells are injected into the bladders of 
immunodeficient rodents, while in the syngeneic models, syngeneic mice/rats cancer cells are 
implanted in immunocompetent animals. The technique for tumor implantation is the same for 
both models: single cell suspensions are injected into the bladder either via an abdominal incision 
or after catheterization. The tumor take rate with this method ranges from 30-100%, but can be 
optimized in different ways. When instilling more tumor cells, increasing the duration time of 
tumor contact with the bladder wall or mechanically/chemically disrupt the bladder mucosa 
before injection of tumor cells, tumor take rates are reported to increase significantly (Chan et al, 
2009). With these techniques, tumors are already formed after <1 week-2 weeks, which is much 
faster than in the chemically induced models. The xenograft model is not suitable to test 
responses to immune therapies, which is often applied to treat bladder cancer, due to the use of 
immunodeficient animals. 
 
2.2.2 Heterotopic models 
In heterotopic models, tumor cells (either animal-specific or primary human cells) are implanted 
at another place in the body than the urinary bladder. Tumor cells are injected subcutaneously, 
usually in the flank or hind leg of the mouse/rat. Again, when working with human cells, 
immunodeficient rodents are needed. Major drawbacks of this model are the low tumor take rate, 
which is only about 35 % for urothelial carcinomas (DeGraff et al, 2013), and the unnatural 
environment for the tumors to grow in. Again, when working with human cells, no 
immunoresponses can be investigated. On the other hand, tumors grow quickly and can be 
detected already 1 week after tumor implantation. Also, tumor growth can be detected by 
palpation, which is easier compared to detecting orthotopic tumor growth (e.g. by MRI or 
histology after sacrifice) (Gabriel et al, 2007).  
 
2.2.3 Genetically engineered models 
The generation of transgenic mice or genetically engineered mice (GEM) is a relative new field in 
bladder cancer research. The first transgenic mouse model was generated in 1999 by Zhang et al. 
In these mice, simian virus 40 (SV40) large T antigen was expressed under the control of an 
urothelium-specific promotor, uroplakin 2 (UpkII). Transgenic mice were found to develop CIS 
(low copy number of SV40T transgene) or CIS accompanied with invasive and metastatic disease 
(high copy number of SV40T transgene) (Zhang et al, 1999). Another possible promotor to drive 
urothelium-specific expression is the Krt19 promotor. Besides SV40 large T antigen, other 
oncogenes that have been expressed in the urothelium in transgenic mice are Hras, Egfr and 
cyclin D1 (Kobayashi et al, 2015).  
A UPKII-driven Cre mouse strain was developed that was able to target genes flanked by loxP-
sites. Some examples of gene targeting with this technique are the following: removal of tumor 
suppressors p53 and/or pRb (He et al, 2009); activation of β-catenin via deletion of loxP-flanked 
exon 3 (Ahmad et al, 2011) and deletion of Ncstn thereby interfering with Notch-signaling 
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(Rampias et al, 2014). Due to the use of the UPKII-promotor, all alterations are urothelium-
specific. Another means to specifically alter gene expression in the urothelium, is delivering Cre-
recombinase-expressing adenovirus into the urothelium, which can delete rodent genes flanked 
by loxP-sites. The delivery of adenovirus is managed through catheterization of the bladder.  
 
PART III: Evans blue 
3.1 Chemical and physical properties 
Evans blue (EB), also named T-1824 or Direct blue 53, is a water-soluble poly-aromatic diazo 
dye, discovered by the American chemist Herbert McLean Evans. Its full IUPAC name is the 
following: tetrasodium (6E,6'E)-6,6-[(3,3'-dimethylbiphenyl-4,4'-diyl)di(1E)hydrazin-2-yl-1-
ylidene]bis(4-amino-5-oxo-5,6-dihydronaphthalene-1,3-disulfonate). Azo compounds contain the 
functional group R-N=N-R‟. The aromatic side groups around the azo bond makes many of the 
azo compounds colored due to absorption of visible light, which is also the case for EB. This dye 
features a very intense blue color with a molar absorption coefficient of 78,100 M-1cm-1 at 626 nm 
(Roberts & Palade, 1995). 
EB has a molecular weight of 960.81 g/mol and a λmax of 605-613 nm (in water). The chemical 
structure and absorption spectrum of EB is given in Figure 1.5. Evans blue appears as a black 
powder or as blue crystals with a green-bronze gloss. The compound is soluble in water from 10 
to 50 mg/ml (at 24.5 °C) (NTP, 1992) and emits a bright red fluorescence upon excitation (λex: 
470 and 540 nm; λem: 680 nm) (Jaffer et al, 2013).  
 
 
Figure 1.5: Chemical structure 
and absorption spectra of Evans 
blue (EB was dissolved in a 
buffered aqueous solution (MOPS, 
pH 7)) (adopted from Müller-Graff 
et al, 2010) 
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3.2 Clinical use 
Evans blue has been used in the past for the determination of the blood volume in humans due 
to its high binding affinity for the plasma protein albumin. The first dye method to determine 
plasma and blood volumes was introduced by Keith et al in 1915. They used a red dye, vital red, 
to calculate plasma volumes. In 1920, Dawson et al tested over 60 different dyes for their 
possible use in blood volume determinations. They found Evans blue to be the best choice. 
Advantages of using EB are that this compound is very slowly eliminated from the blood 
capillaries due to the intense binding with albumin, EB is also non-toxic in high concentrations 
and, very importantly, it is easier to measure the blue color in the plasma compared to the red, 
especially when the sample is hemolyzed. The first reliable method to determine plasma volumes 
with EB was described by Gibson & Evans (1937). Briefly, a measured quantity of the dye is 
injected into the blood stream. After some time intervals (minimum 10 min after injection), blood 
is withdrawn and centrifuged to obtain the plasma. Subsequently, the blue color is measured 
using a spectrophotometer set at 620 nm. Control (undyed plasma) samples undergo the same 
process. Based on the reads of the photometer, plasma volumes can then be calculated. 
Intravenously injected EB solutions were found to be non-toxic in doses up to 20 mg/kg in rats 
(Gibson & Gregerson, 1935). 
Evans blue has been used as the standard plasma marker (with some improvements in the 
technique) until the use of radioisotopes was introduced 20 years later. Main reasons to switch to 
radioisotopes were reports of sensitivity reactions and patient discolorations. However, in some 
cases (pregnant women, children) the use of radiolabeled compounds is not appropriate. 
Therefore, in recent years, the Evans blue dye method has been renewed to a more user-friendly 
method, e.g. same venous site for dye-injection and collection of samples and an easy way to 
correct for hemolysis and turbidity of plasma samples (Jones & Wardrop, 2000). Other uses of 
EB in clinical practice involve the detection of aspirated materials in patients with tracheostomy 
(Belafsky et al, 2003), dye imaging in cardioscopy (Kanai et al, 2000) and, in the past, Evans blue 
was injected into the amniotic sac to diagnose premature rupture of the membranes (Atlay & 
Sutherst, 1970). 
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AIMS AND OUTLINE OF THE STUDY 
At present, white-light (WL) cystoscopy remains the gold standard for bladder cancer detection 
during transurethral resection of the bladder (TURB). However, inspection of the bladder wall 
with white light is not a 100% effective, causing underdiagnoses of small lesions and flat 
carcinoma in situ (CIS). As a consequence, many patients experience recurrences and progression 
to a more advanced stage of the cancer. It is believed that a better detection at initial diagnosis 
leads to fewer recurrences, thereby improving the outcome for patients. For example, it has been 
studied that, by using fluorescence cystoscopy after instillation of fluorescent, tumoritropic 
compounds, detection of bladder tumors improves, decreasing recurrence rates up to one year 
(Burger et al, 2013). Despite its proven efficacy, fluorescence cystoscopy is not routinely used in 
clinical practice, mostly because specific, expensive material is required. An ideal solution would 
be to use a very intensely colored tumoritropic dye in combination with WL cystoscopy. Such a 
compound, Evans blue (EB), was previously investigated by our group. Using spheroids 
composed of normal and malignant urothelial cells, it was shown that EB accumulated to a 
higher extent in the spheroids composed of malignant cells. It was concluded that the compound 
is a possible promising tool as a clinical diagnostic for bladder cancer. 
The general objectives of this project were: 
 To investigate the tumoritropic characteristics of EB in an in vivo orthotopic AY-27 rat 
bladder urothelial cell carcinoma model and hence the feasibility to use EB for the 
detection of non-muscle-invasive bladder cancer 
 To examine the safety of EB intrabladder instillations 
 To gain more insight into the underlying mechanisms of selective EB uptake in tumor 
tissue 
To address the general objectives, the current study has been divided in the following chapters: 
A general introduction is provided in Chapter 1. 
In Chapter 2, the biodistribution of EB in the different layers of the bladder wall (urothelium, 
submucosa and muscle) was compared in normal and tumor-bearing rat bladders after 
intravesical instillation of EB. For this purpose, an orthotopic rat bladder urothelial cell 
carcinoma model was generated by inoculating AY-27 tumor cells into pre-treated rat bladders. 
Ultrastructural differences between healthy and malignant urothelium were investigated by means 
of transmission electron microscopy (TEM). Finally, immunohistochemistry was performed to 
check the differential expression of E-cadherin, desmoglein-1 and claudin-1 in the two urothelial 
tissue types. 
In Chapter 3, the differential accumulation of EB in normal and malignant rat bladders was 
further investigated. The inner walls of the bladders were visually inspected for the presence of 
blue staining after intravesical instillations of EB. Also, the concentrations of EB present in the 
bladder homogenates was quantified after an extraction procedure. Furthermore, the amount of 
EB present in the plasma after intravesical instillations was investigated, as well as the possible 
histological adverse effects of repeated EB instillations. Finally, a transcriptomic analysis of 
malignant and normal rat urothelium was performed with a specific focus on cell adhesion.  
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In Chapter 4, the general conclusions and future perspectives are discussed. 
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ABSTRACT 
 
Objectives: To investigate the possibility of using Evans blue (EB) as a novel diagnostic tool to 
detect bladder tumors with white-light (WL) cystoscopy, in this preclinical study we examined the 
biodistribution of the compound in the different layers (urothelium, submucosa, muscle) of a 
normal rat bladder and a rat bladder bearing a malignant urothelium composed of syngeneic AY-
27 tumor cells.  
Materials and methods: EB was instilled into both normal as well as tumor-bearing rat 
bladders. Following instillation, bladders were removed and snap frozen in liquid nitrogen. The 
distribution of EB in the different layers was quantified using fluorescence microscopy. To gain 
more insight into the mechanism underlying the selective accumulation of EB in tumor tissue, 
bladder sections were prepared for ultrastructural investigations by means of transmission 
electron microscopy (TEM). Besides, we also examined the expression of E-cadherin, claudin-1 
and desmoglein-1 by immunohistochemistry to study the integrity of the bladder wall as these 
molecules are key constituents of adherens junctions, tight junctions and desmosomes, 
respectively. 
Results: In most cases the accumulation of EB in malignant bladders was substantially higher 
than in healthy bladders, at least when 1 mM EB instillations were used. In case of a 1 mM EB 
instillation for 2 hrs, the EB-associated fluorescence in malignant urothelial tissue was 55 times 
higher as compared to the fluorescence found in normal urothelium. Ultrastructurally, malignant 
tissue displayed wider intercellular spaces and a decreased number of cell junction components as 
compared to normal tissue, pointing to defects in the urothelial barrier. No differences in 
expression of E-cadherin were found, whereas desmoglein-1 staining was stronger in the 
membranes of healthy bladder urothelium compared to tumor tissue. Claudin-1 expression was 
negative in all samples tested. 
Conclusion: EB is selectively taken up by tumor tissue after intravesical instillations in rats 
bearing bladder tumors. The lower expression of desmoglein-1 in tumor samples, together with 
the decreased presence of desmosomes observed with TEM, likely imply that desmosomes play 
an important role in the ultrastructural differences between healthy rat urothelium and tumor 
tissue, and secondary to that, to the differential uptake of EB in both tissues. We believe that our 
findings can be useful for future clinical developments in the field of diagnostics for bladder 
cancer. 
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1. INTRODUCTION 
Bladder cancer is a common cancer worldwide, affecting mostly the male elderly population. In 
the western world, this disease is the 4th most common form of cancer in men, following 
prostate, lung and colon cancer [1]. In the US, 73,510 new cases of bladder cancer were recorded 
accompanied with 14,880 deaths in 2012 [2]. In the European Union (EU-27), even higher 
numbers were registered in 2008 (110,500 new cases and 38,200 deaths) [3].  
At first diagnosis, approximately 75% of detected lesions are classified as non-muscle-invasive 
bladder cancer (NMIBC) originating from the urothelium (urothelial cell carcinoma, UCC) [4]. 
These lesions are generally resolved by endoscopic removal of cancerous tissue from the bladder, 
called transurethral resection (TUR). Disappointingly, after a first TUR, up to 30 to 80% of 
patients experience a recurrence of the disease, while a substantial amount of superficial lesions 
will eventually progress to invasive cancer (up to 45% within 5 years) [5]. As a consequence, 
bladder cancer patients require extensive follow-up, which explains the high treatment cost from 
diagnosis to death [6].  
Nowadays, the „gold standard‟ for the visualization of suspicious lesions during TUR is white-
light (WL) cystoscopy. In general, this technique works well in detecting exophytic lesions, but 
small papillary lesions and flat lesions such as carcinoma in situ (CIS) are often underdiagnosed. 
Since the latter superficial lesions are characterized by their malignant potential to progress and 
invade other tissues, efforts need to be made to improve their detection during TUR procedures. 
Recently, the use of fluorescence-guided diagnosis or photodynamic diagnosis (PDD) with 
different tumoritropic compounds (like hexaminolevulinate (HAL) and hypericin) was introduced 
in the urology clinic [7-8]. A recent review investigated the efficacy of PDD over WL cystoscopy 
for NMIBC [9]. It was concluded that PDD significantly improves detection of bladder cancer 
and is more effective for the diagnosis of CIS. A meta-analysis conducted in 2013 confirmed that 
blue-light cystoscopy with HAL improves detection of bladder tumors and reduces recurrence 
rates up to one year [10].  
Despite the many advantages of using PDD over WL cystoscopy, the widespread use and 
implementation of this technique is hampered by the requirement of specific, expensive 
equipment. An interesting alternative to PDD would be the use of WL cystoscopy in 
combination with a dye. One of the compounds under investigation by our group is Evans blue 
(EB), also known as Direct Blue 53 or T-1824, a poly-aromatic water-soluble diazo dye (Figure 
2.1) that has a very intense blue color. Positive results regarding the tumorotropic accumulation 
of this dye using an in vitro spheroid model [11], lead us to investigate EB as a NMIBC tool in an 
established syngeneic orthotopic rat bladder tumor model [12]. The specific accumulation of EB 
in tumor versus healthy urothelium was considered as well as the mechanisms underlying this 
accumulation. The results show that EB accumulated significantly more in malignant urothelium 
compared to healthy urothelium and this specific accumulation was due to defects in the 
urothelial barrier. We believe that EB in combination with WL cystoscopy might be used as a 
clinical application to increase the detection of NMIBC. 
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Figure 2.1: Chemical structure of Evans blue. 
 
2. MATERIAL AND METHODS 
 
2.1 Animals 
Female Fisher rats (F-344) weighing 160-200g were used in all experiments (Charles River 
Laboratories, Lyon, France). Rats were kept in standard filter-top cages and were provided with 
purine chow and water ad libitum. Room temperature was kept constant at 22°C and a 12 hrs 
dark/light cycle was maintained. All animal procedures were performed in compliance with 
national and European regulations and were approved by the animal care and Ethics Committee 
of the University of Leuven (approval number 053/2010). 
 
2.2 Orthotopic AY-27 rat bladder tumor model 
AY-27 cells were used for tumor implantation experiments. Culturing methods and the technique 
used for tumor implantation were described previously by Vandepitte et al [13]. Briefly, rats were 
anesthetized with an intraperitoneal injection of 45 mg/kg sodium pentobarbital (Nembutal) and 
placed on an animal board kept at 25°C to retain body temperature. Rat bladders were then 
catheterized via the urethra with a plastic 18-gauge intravenous catheter. Bladders were emptied 
and flushed once with 0.3 ml PBS. Subsequently, the bladder mucosa was mildly disrupted by 
performing an acid/base treatment: first 0.3 ml of a 0.1 N HCl solution was injected for 20 s, 
followed by an injection of 0.3 ml of a 0.1 N NaOH solution for 20 s. Afterwards, the bladder 
was flushed several times thoroughly with 0.3 ml PBS. AY-27 cells (4 x 106 cells/0.3 ml) were 
inoculated into the bladder for one hour. Rats were turned 90° every 15 min to expose the whole 
bladder wall to the tumor cells. After the procedure, the catheter was removed and rats were able 
to void spontaneously. For all injections, syringes of one ml and 18-gauge needles were used. 
Importantly, prior to trypsinization, cells were incubated for 30 min with the green fluorescent 
cell tracker 3,3‟-dioctadexyloxacarbocyanine perchlorate (DiO, Molecular Probes Inc, OR, USA) 
in the tumor accumulation experiments to visualize the cells after implantation.  
To obtain an intact and superficial non-muscle-invasive bladder tumor, in our hands malignant 
cells needed to grow for one to three days after cell inoculation [13]. Therefore, all experiments 
were performed two days after the inoculation of AY-27 cells into the rat bladder. 
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2.3 Biodistribution experiment 
 
2.3.1 Bladder instillation of Evans blue 
Evans blue powder (Sigma-Aldrich) was dissolved in PBS before intrabladder application. Rats 
were anesthetized with an intraperitoneal injection of 45 mg/kg sodium pentobarbital and 
catheterized with an 18-gauge catheter. Afterwards, 0.3 ml of an EB solution was instilled. 
Different concentrations and different instillation times were tested during preliminary 
experiments (50 µM, 1, 2.5, 5 mM – 0.5, 1, 2 hrs). Finally, three instillation conditions were 
investigated into more detail: 1 mM EB for 1 and 2 hrs, and 2.5 mM EB for 1 hr. For each 
experiment, 24 rats were divided into 4 groups: a tumor bladder group, instilled with EB (n=6), a 
tumor bladder group instilled with PBS (n=6), a normal bladder group, instilled with EB (n=6) 
and a normal bladder group, instilled with PBS (n=6). After the instillation of EB or PBS, rats 
were euthanized, the bladders were dissected, cut open and immediately embedded into Tissue 
Tek medium (Miles Inc, Elkart, IN, USA). Consequently, the bladders were snap-frozen in 
isopentane-cooled liquid nitrogen. Cryostat microtomy was performed to obtain 5-µm bladder 
sections. 
2.3.2 Imaging of fluorescence 
Pictures of the bladder wall sections were taken with an Axioskop 2 plus fluorescence 
microscope (Carl Zeiss, Göttingen, Germany), illuminated by a 100-W mercury lamp. 
Fluorescence images were taken using a light-sensitive charge-coupled device (CCD) digital 
camera (Axiocam HR, Carl Zeiss, Göttingen, Germany). To maintain uniformity concerning 
fluorescence intensities, study parameters such as objective lenses, excitation and emission filters 
and exposure time were kept constant. 
Fluorescence imaging of EB was done using a filter set with a 510-560 nm band-excitation filter 
and a 590 nm long-pass emission filter. The fluorescence of DiO marked the presence of tumor 
tissue and could be visualized with a different filter set (450-490 nm band-pass excitation filter 
and 515-565 nm band-pass emission filter). 
After capturing the fluorescence, the sections were stained with a standard hematoxylin and eosin 
(H&E) staining for histological examination. 
2.3.3 Quantification of fluorescence 
For each rat, two randomly selected places in the bladder were examined. From each of those 
sections, histological intact regions (minimum of two, size appr. 2 mm on 500 µm) were 
delineated and the fluorescence of the different bladder layers (urothelium, submucosa, muscle) 
was quantified using ZEN 2012 (version 1.1.0.0, Carl Zeiss Microscopy GmbH) quantification 
software. Corrections for autofluorescence were made by subtracting fluorescence values 
measured in tissue of control animals. 
2.3.4 Statistical analysis 
Results are expressed as means + SEM. To compare the fluorescence of EB in tumor rat 
bladders versus healthy rat bladders, a non-parametric Mann-Whitney U test was performed 
(GraphPad prism software, significance level of 0.05). 
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2.4 Transmission electron microscopy 
Bladders were removed from one control rat and one tumor-instilled rat. Small pieces of the 
bladders were cut out and fixed in cold 2% glutaraldehyde, buffered at pH 7.3 with 50 mM Na-
cacodylate and 150 mM sucrose for 20 hrs. Postfixation was done in 2% osmium tetroxide in the 
same buffer. After the fixation steps, tissues were dehydrated in a graded acetone series, after 
which they were embedded in Araldite and sectioned with a Leica EMUC6 ultramicrotome. 
Sections of 1 µm thickness were obtained, stained with methylene blue and thionin and examined 
under a light microscope (Carl Zeiss, Göttingen, Germany). 70 nm-thin sections were stained 
twice with lead citrate and uranyl acetate and examined using a Zeiss EM 900 electron 
microscope.  
2.5 Immunohistochemistry 
Control (n=4) and bladders bearing a malignant urothelium (n=4) were examined for the 
presence of E-cadherin, claudin-1 and desmoglein-1. These specific molecules were chosen as 
they are key constituents of adherens junctions, tight junctions and desmosomes, respectively. 
Following primary antibodies were used: rabbit polyclonal anti-E-cadherin antibody, dilution of 
1/500 (ab53226; Abcam, Cambridge, UK), rabbit polyclonal anti-claudin-1 antibody, dilution of 
1/100 (ab15098; Abcam, Cambridge, UK) and rabbit polyclonal anti-desmoglein-1 antibody, 
dilution of 1/200 (sc-20114; Santa Cruz Biotechnology). Immunohistochemistry was performed 
on paraffin sections according to the protocol described in the BOND polymer refine detection 
kit. As a positive control, rat skin was used. Background staining was tested by adding the 
secondary antibody („dual envision‟) without the primary antibody. Semi-quantitative analysis was 
performed by a trained histologist by scoring the intensity of expression as absent, weak, 
moderate or strong. Also the localization of expression was considered as present in the 
membranes, cytoplasm or nucleus. 
 
3. RESULTS 
 
3.1 Biodistribution experiment 
All animals instilled with AY-27 tumor cells (n=36) survived the implantation procedure and 
were found to have a superficial form of bladder cancer after two days of tumor growth. This 
was confirmed by the histological analysis and the presence of the fluorescent tumor marker 
DiO. More specifically, pathological examination indicated that tumors generated were high-
grade carcinoma in situ. No invasions in underlying tissue were seen, while nuclei were enlarged, 
variable in size and arranged disorderly (anisokaryosis). Also a loss of polarization was noticed. 
Examples of H&E stained 5-µm sections are depicted in Figure 2.2.  
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Control and tumor-inoculated rat bladders were instilled with EB. EB emits a bright red 
fluorescence upon excitation, and since the blue color in the 5-µm sections of rat bladders is too 
weak to be quantified, the biodistribution of the compound as present in the different layers of 
the bladder (urothelium, submucosa, muscle) was investigated by fluorescence microscopy.  
Figure 2.3 depicts some representative pictures of the 5-µm bladder sections after a 2-hrs 
instillation of EB (1 mM). The fluorescence of the compound is shown with the corresponding 
H&E stainings of the 5-µm samples. The red fluorescence is weak and confined to the outside of 
the bladder wall in control bladders (2.3A), while a clear accumulation in the superficial tumor 
cells is visible in the tumor samples (2.3E). Also in the deeper muscle layer significant 
fluorescence is visible (2.3G). In control samples, no fluorescence of EB is noticed in the 
muscularis (2.3C). Since AY-27 tumor cells can be visualized by the green fluorescent cell tracker 
DiO, the superficial nature of the tumor is evident (2.3I). Importantly, areas of green 
fluorescence (tumor) and red fluorescence (EB) show a good correlation (2.3J). 
 
Figure 2.2: Example of H&E staining. 
The different layers of a tumor rat bladder (left side) and a normal rat 
bladder (right side) are depicted in this picture. Original magnification = 
200x. 
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Figure 2.3: 5-µm sections of rat bladders after instillation of Evans blue.  
Fluorescence photomicrographs and the corresponding H&E stainings of the frozen 5-µm 
sections after a 2 hrs instillations of Evans blue (1 mM) in control (A-D) and tumor-instilled rat 
bladders (E-J). Figures A and B visualize the urothelium and underlying submucosa, figures C 
and D the deeper muscle layer of healthy rat bladders. Figures E and F show the tumor layer and 
submucosa, figures G and H the muscle layer of tumor-instilled rat bladders. Visualization of 
tumor cells by DiO (I) and the overlay of DiO fluorescence and Evans blue fluorescence (J). Red 
= fluorescence of Evans blue; green = fluorescence of DiO, which marks the presence of tumor 
cells; yellow = overlap of the fluorescence of EB and DiO. 
Original magnification = 200x, gain = 3, exposure time = 200 ms. 
 
Figure 2.4 compares quantitatively the accumulation of EB in the different layers, as measured by 
the fluorescence present, after an instillation of 1 mM EB for 1 and 2 hrs, and an instillation of 
2.5 mM EB for 1 hr. All 72 animals were included in the analysis (n = 24 for each graph, i.e. 12 
animals in case of tumor conditions and 12 animals in case of healthy bladder conditions). The 
accumulation in tumor urothelium is in line with the conditions tested, i.e. a higher accumulation 
was found using 1 mM EB in the 2 hrs-condition as compared to the 1-h condition, and using 
the 2.5 mM condition as compared to the 1 mM condition (both 1 h incubation). The 
concentrations in the underlying tissues (submucosa, muscle) in general follow this pattern. With 
a longer instillation time (2 hrs) EB piles up in the muscle layer of the tumor bladders. In most 
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cases the accumulation of EB in the tissues of healthy bladders is substantially lower than in the 
malignant conditions, at least when 1 mM EB instillations were used. In one condition (2.4B) EB 
fluorescence in malignant urothelial tissue was 55 times higher as compared to the fluorescence 
found in normal urothelium. Comparable high concentrations (although still statistically different) 
were found in the tissues of both healthy and tumor bladders in the 2.5 mM condition (2.4C). 
 
 
 
 
 
Figure 2.4: Quantification of 
fluorescence after Evans blue 
instillation.  
The fluorescence intensity in the 
different layers of normal rat 
bladders vs tumor-bearing rat 
bladders is compared.  Conditions: 
(A) 1 mM EB, 1 hr instillation, (B) 
1 mM EB, 2 hrs instillation, (C) 2.5 
mM, 1 hr instillation. Means + 
SEM are shown. *** = p-value < 
0.0001, ** = p-value < 0.01, * = p-
value < 0.05. 
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3.2 Transmission electron microscopy 
In order to explain the differential accumulation of EB in both bladder types, ultrastructural 
differences were investigated using TEM (Figures 2.5 and 2.6). 
From Figure 2.5 it is clear that cells of the urothelium from normal bladders are tightly 
interconnected. Components of the junctional complex can easily be found: tight junctions, 
adherens junctions and desmosomes can be distinguished from the apical to the basal surface. 
These cell adhesion structures are omnipresent and evident. In contrast, the photomicrographs of 
the tumor samples (Figure 2.6) show a very different image: tumor cells are loosely attached to 
each other and clear cell adhesion structures are difficult to find. This first might seem as an 
incompetence of the tumor cells to properly attach to each other. However, joining tumor cells 
are also characterized by the presence of many microvillar extensions thereby enlarging the 
connecting surface between tumor cells.  
 
 
Figure 2.5: Transmission electron photomicrographs of normal rat bladder.  
(A) Overview photomicrograph (light microscopy) of methylene blue and thionin-stained bladder 
wall (original magnification = 400x, u = urothelial cell layer); (B,E) Electron photomicrographs 
of uranyl acetate and lead citrate-stained urothelium (1100x), the boxed areas are shown at higher 
TEM magnification (7000x) in C and F, respectively. (D, G) Close-ups of the junctional 
complexes are given (D, 12000x; G, 20000x). Arrows point to different components of the 
junctional complex: white arrows = desmomes, red arrows = adherens junctions and black 
arrows = tight junctions. 
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Immunohistochemistry 
No differences in E-cadherin immunostaining were found between the tumor bladder samples 
and the control bladder samples. All eight samples showed a weak membrane staining in the 
deeper layers of the urothelium and a stronger staining of the membranes in the superficial 
urothelial layers (Fig. 2.7A-B). Claudin-1 staining was negative in all samples tested (data not 
shown), while a clear difference was observed between healthy rat bladder urothelium and tumor 
tissue for desmoglein-1 (Fig. 2.7C-D): healthy bladder urothelium is characterized by a strong 
staining of the membranes, while membranes of tumor tissue stain only weakly positive. 
Figure 2.6: Transmission electron photomicrographs of tumor rat bladder.  
(A) Overview photomicrograph (light microscopy) of methylene blue and thionin-
stained bladder wall (original magnification = 400x, t = proliferating tumor cells). (B-E) 
Electron photomicrographs of uranyl acetate and lead citrate-stained cell adhesion sites 
between tumor cells; magnifications: 3000x (B, C) and 7000x (D, E); Arrows point to 
different components of the junctional complex: white arrow = desmosome, red arrow 
= adherens junction, black arrows = microvillar extensions. 
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4. DISCUSSION 
 
To investigate the possibility of using the water-soluble dye Evans blue (EB) as a novel diagnostic 
tool to detect bladder tumors with white-light (WL) cystoscopy, we examined the biodistribution 
of the compound in the different layers (urothelium, submucosa, muscle) of a normal rat bladder 
and a rat bladder bearing a malignant urothelium composed of syngeneic AY-27 tumor cells. In 
this preclinical study we exploited the bright fluorescence of EB to be able to assess the relative 
amount of EB in thin sections (5-µm) of the different layers of the bladder. However, the 
fluorescence-based methodology applied for this purpose does not preclude the possibility to use 
EB as a visual marker of malignant bladder lesions in combination with WL cystoscopy in the 
clinic. EB features a very intense blue color (molar absorption coefficient = 78,100 M-1cm-1 at 
626 nm) and we anticipate that its accumulation in multiple layers of malignant cells will results in 
a true “staining” of the tissue which can be observed by white-light (WL) cystoscopy.     
In all cases, EB accumulated substantially more in malignant urothelial tissue as compared to 
normal urothelium. However, instillations of EB in rat tumor bladders also resulted in some 
accumulation of EB in the inner layers of the bladder, i.e. the muscle layer. This was observed 
especially when applying longer instillation times. We hypothesize that the formation of tumor 
cells disturbs the normal barrier function of the urothelium, causing EB to penetrate by passive 
diffusion. With time, the EB eventually accumulates in the muscle layer of the bladder for which 
Figure 2.7: Photomicrographs of bladder urothelium immunostainings 
Representative photomicrographs of the rat bladder urothelium after 
immunostaining with E-cadherin (A-B) and Desmoglein-1 (C-D). A and C 
represent pictures of malignant urothelium; B and D show pictures of healthy 
urothelium. Original magnification = 200x. 
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the compound seems to exhibit a higher affinity than for submucosal tissue. This is not 
necessarily a problem and might even aid to detect bladder tumors. The human bladder wall is 
only a few mm thick (3.35 mm on average [14]) and it is anticipated that the accumulation of EB 
in the muscle layer below malignant lesions will also be picked up by cystoscopy, thereby 
increasing the chance of detection of bladder tumors.  
Interestingly, an identical AY-27 tumor bladder rat model as employed in this study was used to 
examine the accumulation of PVP (polyvinlypyrrolidone)-hypericin and HAL-induced PpIX 
(protoporphyrin IX) in the rat bladder wall [15-16]. PVP-hypericin showed a 3.5-fold difference 
of accumulation in tumor urothelial tissue versus normal urothelium. In case of 8 mM HAL 
instillations, PpIX quantities extracted from tumor bearing bladders were ca. 3.75-fold higher 
than the amount found in normal bladders. Since hypericin but especially HAL are routinely used 
in the urologic clinic for bladder instillation followed by PDD, and since similar to higher 
differential concentrations were observed in this study using EB, we anticipate that EB could 
become an interesting candidate for dye-guided WL cystoscopy.  
Moreover, of critical importance, multiple studies mention the use of EB in clinic practice 
without adverse reactions. Clinical use of this dye include the determination of blood volume 
[17], evaluation of blood vessel and cellular membrane permeability [18], detection of aspirated 
materials in patients with tracheostomy [19] and guidance during amniocentesis [20]. The 
widespread use of EB for different applications in the clinic indicates that the risks in using this 
compound are minimal. 
To gain more insight into the mechanism underlying the selective accumulation of EB in tumor 
tissue, bladder sections were prepared for ultrastructural investigations. The urothelium of 
healthy rat bladders compared to tumor rat bladders show clear differences. Healthy urothelium 
is characterized by the presence of clear and distinct cell junction components. This is in line with 
the usual arrangement found in human bladder samples [21]. Conversely, in tumor samples, cells 
were found to be loosely attached to each other. Cell junction components are sometimes 
present, but not in an orderly manner as found in healthy urothelium. Similar ultrastructure 
characteristics, i.e. wide intercellular space and decreased number of cell junction components 
(including desmosomes), were noticed in spheroids composed of malignant cells derived from 
established bladder cancer cell lines [11] and also in clinical samples of superficial bladder tumors 
[22-23]. These morphologic characteristics might point to a loss of cohesiveness in bladder 
carcinoma and might explain the penetration of EB into the barrier-defective tumor cells of our 
rat model. Furthermore, most tumor cells in our experiments are characterized by the presence of 
microvillar-like extensions, the function of which is unclear. In the study of Arum et al [24], it is 
proposed that these microvilli might serve to prevent tumor eradication by the host immune 
system. Another article suggests that a greater number of microvilli appear on tumor cells that 
have a higher growth potential and metastatic ability [25].  
Next to the characterization of ultrastructural aspects, the expression of three different cell 
adhesion molecules was investigated immunohistochemically. The cell adhesion molecules were 
chosen based on their presence in different kind of junctions: E-cadherin as a component of 
adherens junctions, claudin-1 as an element of tight junctions and desmoglein-1 as a component 
of desmosomes. No differences in expression of E-cadherin were found, whereas desmoglein-1 
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staining was stronger in the membranes of healthy bladder urothelium compared to tumor tissue. 
Claudin-1 expression was negative in all samples tested. 
At first sight, our findings therefore contradict the results of the study of Arum et al [24]. In their 
work, the expression of E-cadherin and desmoglein1+2 was investigated in sections of AY-27 cell 
inoculated rat bladders. The authors found that E-cadherin is expressed in normal epithelia but 
not in tumor tissue, while desmoglein1+2 expression was negative in healthy as well as tumor 
bladder. The reason for this discrepancy might be the use of different periods of tumor growth: 
to obtain a superficial form of bladder cancer, tumor cells proliferated for only 2 days in our 
study, whereas in the study by Arum et al tumors grew for one to three weeks. It is possible that 
the decrease of E-cadherin expression only occurs later during tumor progression (the so-called 
cadherin switching), an observation that is also found in studies of the human bladder [26]. 
Studies on the expression of desmoglein-1 in bladder cancer are rare. It is however known that a 
reduced or negative expression of desmoglein-1 is associated with malignant properties in 
carcinoma of the skin and squamous cancers [27-28].  
The lower expression of desmoglein-1 in tumor samples, together with the decreased presence of 
desmosomes observed with TEM, might imply that desmosomes play an important role in the 
ultrastructural differences between healthy rat urothelium and tumor tissue, and secondary to 
that, to the differential uptake of EB in both tissues. Presumably, other factors also play a role. 
Clearly, these aspects need to be investigated further in order to understand better the 
mechanism of accumulation of EB in bladder tumor tissue. 
We believe that our findings can be useful for future clinical developments in the field of 
diagnostics for bladder cancer. Most importantly, EB is already used for years in a clinical setting 
for other kinds of applications without adverse reactions. If these positive results using EB can 
also be repeated in a human setting, we expect a substantial benefit for patients and society by 
implementing the protocol of EB instillations combined with WL cystoscopy in comparison with 
the expensive PDD procedure. 
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ABSTRACT 
Purpose: Photodynamic diagnosis (PDD, also known as fluorescence cystoscopy) improves the 
detection of non-muscle-invasive bladder cancer (NMIBC). Nonetheless, white-light (WL) 
cystoscopy remains the technique routinely used in the urological clinic. A cheaper but equally 
performant alternative to PDD might encompass the use of a tumoritropic dye with an intense 
color in combination with WL cystoscopy. Using a preclinical setting, we investigated in this 
study some practical aspects of the use of Evans blue (EB) for the possible future detection of 
NMIBC using WL cystoscopy.  
Materials and methods: A solution of 1 mM and 5 mM EB was instilled into healthy and AY-
27 tumor-bearing rat bladders for 2 h and 1 h, respectively. Bladders were then rapidly dissected 
and inner walls were inspected for EB using WL stereomicroscopy. EB present in the bladders 
and the plasma was also quantified using HPLC analysis. To assess the effects of repeated 
instillations on normal rat bladders, EB was instilled for seven consecutive days, after which the 
bladder wall was investigated histologically. To gain insight into the mechanism underlying the 
selective accumulation of EB in malignant urothelium, RNA sequencing of LCM-dissected 
urothelial tissue and subsequent comparative analysis were performed, with a specific focus on 
cell adhesion. 
Results: In both conditions tested, concentrations of EB were substantially higher in malignant 
bladders in comparison with healthy bladders, matching the blue staining of the inner bladder 
wall observed by WL stereomicroscopy. In case of a 1 mM EB instillation for 2 h, EB 
concentrations were 5.5-fold higher in the tumor condition. EB was equally present in the plasma 
of healthy subjects and tumor-bearing subjects, though at low concentrations. EB did not cause 
any abnormalities in the urothelium after a 7-day repeated instillation in normal rats. RNA 
sequencing of the urothelium indicated an abnormal expression of many genes related to cell 
adhesion in malignant urothelium compared with the normal situation, an observation that was 
confirmed by the KEGG enrichment analysis. 
Conclusion: We believe that our findings can be important for future clinical developments in 
the field of diagnostics for bladder cancer. Implementing the cheaper protocol of EB instillations 
in combination with WL cystoscopy might offer a benefit for patients and society in comparison 
with the expensive photodynamic procedure.    
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1. INTRODUCTION 
Bladder cancer is an important health issue worldwide, with an estimated 429,000 new cases 
accompanied with 165,000 deaths in 2012 [1]. Importantly, the management of bladder cancer 
contributes enormously to medical costs, with bladder cancer having the highest lifetime 
treatment cost per patient for all cancers [2]. This is mainly due to the high recurrence rates of the 
disease, expensive treatments and the necessity for frequent surveillances [3]. Little progress has 
been made in research to understand and treat bladder cancer causing the outcomes of this 
disease to have changed very little in the past three decades. This is in stark contrast with the 
significant progress in the 5-yr survival rates for other urothelial malignancies, like kidney and 
prostate cancer, during this period [4].  
At initial diagnosis, 70-75% of bladder cancers are classified as non-muscle-invasive urothelial cell 
carcinomas, tumors from urothelial origin confined to the mucosa or submucosa [5]. The 
standard treatment for these lesions is an endoscopic removal of the malignant tissue, called 
transurethral resection of the bladder (TURB). Usually, a white-light cystoscope is used during 
TURB to visualize the tumors. White-light (WL) cystoscopy works sufficiently for the detection 
of exophytic tumors, but small papillary tumors and flat tumors such as carcinoma in situ (CIS) 
are often missed during the procedure, leading to underdiagnosis and eventually causing 
recurrences and progression. Up to 30 to 80 % of patients experience a recurrence of bladder 
cancer after a first TURB, while up to 45 % of patients are faced with progression to invasive 
cancers [6]. The main goal of future non-muscle-invasive bladder cancer (NMIBC) treatments is 
to reduce recurrences and progression, thereby decreasing the costs of extensive follow-ups and 
improving the outcomes for patients with bladder cancer. To achieve this goal, detection during 
TURB procedures needs to be improved. Fluorescence-guided diagnosis or photodynamic 
diagnosis (PDD) after instillation of tumoritropic (pro-) fluorescent compounds has been shown 
to improve detection of tumors in clinical practice. The compound most often used for this 
purpose is hexaminolevulinate (HAL, Hexvix®/Cysview®). A recent review investigated the 
efficacy of PDD over WL cystoscopy for NMIBC [7]. It was concluded that PDD significantly 
improves detection of bladder cancer and that this technique is more effective for the diagnosis 
of CIS. A meta-analysis conducted in 2013, including 10 publications, confirmed that blue-light 
cystoscopy with HAL improves detection of bladder tumors and reduces recurrence rates up to 1 
year [8]. Despite proven efficacy of PDD and recommendations by experts when CIS or high-
grade tumors are expected [9], WL cystoscopy remains the technique routinely used in the 
urological clinic. This is mainly due to the expensive, specific equipment that is needed to 
perform PDD. 
A possible alternative to PDD would be to use a tumoritropic dye with an intense color in 
combination with WL cystoscopy. Such a compound, Evans blue (EB), was previously 
investigated in vitro and in vivo. In the study of Roelants et al [10], EB accumulated significantly 
more in spheroids composed of malignant urothelial cells compared to spheroids derived from 
normal human urothelial cells. Elsen et al [11] studied the accumulation of EB in an orthotopic 
rat NMIBC model. The biodistribution of EB was examined in the different layers of healthy rat 
bladders and rat bladders bearing a malignant urothelium by quantifying the fluorescence of EB. 
It was concluded that EB is selectively taken up in tumor tissue when using a 1 mM instillation 
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concentration and that this specific accumulation is possibly due to urothelial defects in tumor rat 
bladders.  
In this study, the feasibility to use EB for the detection of NMIBC in the orthotopic rat model 
was further investigated using a 1 mM and a 5 mM instillation concentration. We applied WL 
stereomicroscopy at low magnification to visually inspect the accumulation of EB in the inner 
malignant and the normal bladder wall, and quantified the amount of EB present in homogenates 
of tumor bladders and healthy bladders. Furthermore, the amount of EB present in the plasma 
after intravesical instillation was investigated, as well as the possible histological adverse effects of 
repeated EB instillations. The rat NMIBC tumor model was characterized into more detail by a 
transcriptome analysis of malignant and normal rat urothelium with a specific focus on cell 
adhesion. The aim of this analysis was to further investigate our previous hypothesis [11] that EB 
is able to selectively accumulate in tumor tissue due to defects in the urothelial barrier. 
 
2. MATERIAL AND METHODS 
2.1 Animals 
Female Fisher rats (F-344) weighing 160-200g were used in all experiments (Charles River 
Laboratories, Lyon, France). Rats were kept in standard filter-top cages and were provided with 
purine chow and water ad libitum. Room temperature was kept constant at 22°C and a 12 hrs 
dark/light cycle was maintained. All animal procedures were performed in compliance with 
national and European regulations and were approved by the animal care and Ethics Committee 
of the University of Leuven (approval number 142/2014). 
2.2 Chemicals and reagents 
Evans blue (EB), naphtol blue black (NBB), ureum, 2-mercapto-ethanol, tetrabutylammonium 
hydroxide and tetrabutylammonium dihydrogen phosphate were purchased from Sigma-Aldrich. 
Chloroform was obtained from Acros Organics, 2-propanol from Chem-Lab and acetonitrile 
from Fisher Chemical. EB powder was dissolved in ultrapure water (milli-Q®) immediately 
before instillation. 
2.3 Sedation and catheterization of animals 
For all experiments, rats were anesthetized with an intraperitoneal injection of 45 mg/kg sodium 
pentobarbital (Nembutal) and placed on an animal board kept at 25 °C to retain body 
temperature. Rat bladders were then catheterized via the urethra with a plastic 18-gauge 
intravenous catheter (22-gauge catheters were used in the repeated instillation experiment). 
2.4 Orthotopic AY-27 rat bladder tumor model 
2.4.1 Tumor cell line 
AY-27 cells, originally developed by Dr. S. Selman and Dr. J. Hampton (Ohio Medical College, 
USA), were cultured in 175 cm2 culture flasks at a temperature of 37 °C in a humidified 
atmosphere, containing 5% CO2 and 95% air. Cells were grown as a monolayer in minimal 
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essential medium (MEM) with Earle‟s salts, supplied with 2 mM L-glutamine, 1% 
antibiotic/antimycotic solution, 1% non-essential amino acids, tylosine (60 µg/ml) (Eli Lilly, 
Brussels, Belgium) and 10% fetal calf serum (FCS). Cell culture medium and supplements were 
purchased from Invitrogen (Belgium). 
Cells were used for animal experiments between passage 5 and 15. After reaching confluency, 
cells were washed twice with PBS (pH 7.4), trypsinized and collected after centrifugation. Cells 
were counted with a Coulter Z1 particle counter (Coulter Electronic, Luton, UK) and 
resuspended in MEM in a concentration of 4 x 106 cells/0.3 ml.  
2.4.2 Tumor model 
Subsequently, the AY-27 cells were used for inoculation in our rat bladder tumor model. Rats 
were anesthetized and catheterized as described in the section above. Afterwards, bladders were 
emptied and flushed once with 0.3 ml PBS. The bladder mucosa was then mildly disrupted by 
performing an acid/base treatment: first 0.3 ml of a 0.1 N HCl solution was injected for 20 s, the 
solution was removed and immediately followed by an injection of 0.3 ml of a 0.1 N NaOH 
solution for 20 s. After removal of the NaOH solution, the bladder was flushed several times 
thoroughly with 0.3 ml PBS. AY-27 cells (4 x 106 cells/0.3 ml) were inoculated into the bladder 
for one hour. Rats were turned 90° every 15 min to expose the whole bladder wall to the tumor 
cells. After the procedure, the catheter was removed and rats were able to void spontaneously. 
For all injections, syringes of one ml and 18-gauge needles were used.  
To obtain an intact, high-grade non-muscle-invasive bladder tumor, malignant cells needed to 
grow for two days after cell inoculation [11]. Therefore, all experiments were performed two days 
after the inoculation of AY-27 cells into the rat bladder. 
 
2.5 Accumulation of EB in rat bladders and plasma after intravesical instillation 
2.5.1 EB administration and visual inspection of inner wall rat bladder 
After sedation and catheterization of the animals, the EB solution was instilled in the bladders. 
Two conditions were tested: 1 mM EB instillation during 2 hrs and 5 mM EB instillation during 1 
h in healthy rats (n = 5 per condition) and rats with bladder tumors (n = 5 per condition). In case 
of a 2-hrs instillation period, rat were turned 90° every 30 min, in case of a 1-hr instillation 
period, this was done every 15 minutes. After the instillation periods, rat bladders were 
thoroughly flushed with PBS to remove all EB residues in the bladder. Rats were then 
euthanized, bladders were rapidly dissected and the inner wall was visually inspected for blue dye 
accumulation using WL stereomicroscopy (Leica MZ10 F) at low magnification. Pictures were 
taken with a DFC310 FX digital camera run by Leica Application Suite software (version 3.6.0). 
Afterwards, the bladders were extracted (see further). 
 
2.5.2 Blood sampling 
Healthy (n = 3 per condition) and tumor-bearing rats (n = 3 per condition) were instilled with 1 
mM EB for 2 hrs or with 5 mM EB as described in the section above. Immediately after the 1 or 
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2 hrs-instillation periods, bladders were flushed thoroughly and blood was taken via the tail vein 
of living animals using a wing needle (Venoflux, 0.5 mm G25). Blood was collected into 200 µl 
tubes with lithium-heparin (Microvette®, Sarstedt) to prevent coagulation of blood. The tubes 
were subsequently centrifuged at 2000 rpm for 15 min to separate plasma from blood cells. Three 
hours after the first blood sampling, blood was collected a second time from the same rats and 
processed as described before. After the second blood sampling, rats were euthanized. 
 
2.5.3 Extraction procedure 
The extraction procedure was based on the method described by Gardner [12]. Shortly, in case of 
extraction from bladder samples, the procedure was as follows: the bladder was transferred in a 
50-ml falcon tube and 100 µl/100 mg bladder of a 15 µg/ml aqueous solution of the internal 
standard (IS), naphtol blue black, was added. Napthol blue black (NBB) was chosen as an 
internal standard because of its structural similarity with the analyte. Then, 100 µl/100 mg 
bladder of an 8 M ureum/2-mercaptoethanol (125:1) solution was added to the mixture. After 
vortexing, 200 µl/100 mg bladder of a 0,1 M tetrabutylammonium hydroxide solution was added, 
followed by 6 ml/100 mg bladder of chloroform/2-propanol (83:17). This mixture was 
homogenized with a T25 basic Ultra-Turrax® (IKA-WERKE). After homogenization, the tubes 
were shaken vigorously for 15 min and centrifuged at 500 g for 5 min. The upper layer was 
removed with a pipette and the remaining organic layer, containing EB and NBB, was transferred 
to a new 15-ml falcon tube. Subsequently, the samples were evaporated with a slow stream of 
nitrogen at 30 °C. 
For plasma samples, the extraction procedure was identical as described above, with 100 µl 
plasma corresponding to 100 mg bladder tissue. The homogenization step was omitted from the 
procedure.  
 
2.5.4 Preparation of samples for HPLC analysis 
Dried samples were redissolved in 500 µl or 200 µl of ultrapure water (milli-Q®) in case of 
bladder or plasma samples, respectively. The solution was vortexed and transferred to 500 µl 
tubes that were centrifuged for 5 min at 12,000 rpm. From the clear supernatant, 20 µl was 
manually injected into the HPLC system. 
 
2.5.5 HPLC method for determination of EB 
The samples were analyzed on LaChrom Elite HPLC system (VWR Hitachi) equipped with diode 
array detection (L-2450). Chromatographic separation was performed on a Phenomenex reversed 
phase column, type Luna 3u C18 [150 x 4.6 mm 3 µm] attached to a Phenomenex guard column 
C18 (4 x 3 mm). The column was operated at a flow rate of 1 ml/min at 40 °C (detection 
wavelength: 614 nm). Acetonitrile: phosphate buffer (pH 7, 0.067 M) (45:55) with 2 mM 
tetrabutylammonium dihydrogen phosphate was used as mobile phase. 
 
 
Chapter 3: Evans blue-mediated white-light detection of NMIBC: feasibility and safety study 
 
43 
  
2.5.6 Validation of HPLC method 
A calibration curve was generated to test the linearity of the method. Seven different solutions of 
EB were made in ultrapure water (milli-Q®), with concentrations of EB ranging from 0.25 to 16 
µg/ml. NBB was added to yield a final concentration of 15 µg/ml. The standard solutions were 
injected three times and analyzed according to described procedures. 
To test the recovery of EB, fetal calf serum (FCS) (n=4) was spiked with EB and NBB to obtain 
final concentrations of 8 µg/ml and 7.5 µg/ml, respectively. After addition of EB and NBB, 
samples were incubated at 37 °C for 1 h to enable binding between EB and albumin present in 
FCS. After the incubation period, samples were extracted according to the procedure described 
above for plasma samples. Subsequently, samples were injected and analyzed. The theoretical 
concentration of EB was compared with the concentration obtained by the HPLC method. 
2.5.7 Statistical analysis 
Results are expressed as means + SEM. To compare the concentration of EB in the different 
conditions, a non-parametric Mann-Whitney U test was performed (GraphPad prism software, 
significance level of 0.05). 
 
2.6 Repeated intrabladder instillation of Evans blue 
Healthy rats were instilled with EB instillation solutions for 7 consecutive days. Concentrations 
of 1 mM and 5 mM were tested, PBS instillations served as a control (n = 3 per condition). Each 
day, rats were anesthetized and catheterized via the urethra with a plastic 22-gauge intravenous 
catheter. Bladders were emptied and flushed once with 0.3 ml PBS. Subsequently, 0.3 ml of the 
EB solution was injected into the bladder. Rats were turned 90° every 15 min to expose the 
whole bladder wall to the EB solution. After a 1-hour period, EB was removed and the bladder 
was flushed several times with 0.3 ml PBS. The catheters were removed and rats were allowed to 
void spontaneously. After the last instillation on day 7, rats were euthanized, bladders were 
removed, cut open and immediately transferred into Tissue Tek medium (Miles Inc, Elkart, IN, 
USA). Consequently, the bladders were snap-frozen in isopentane-cooled liquid nitrogen. 
Cryostat microtomy was performed to obtain 5-µm bladder sections. 
Bladder sections were stained with a standard hematoxylin and eosin (H&E) staining to examine 
the bladder wall histologically. Afterwards, bladder sections were blindly analyzed by a trained 
histo-pathologist. Photomicrographs of the bladder cryosections were taken at different 
magnifications with a Zeiss light microscope (Carl Zeiss, Göttingen, Germany). 
 
2.7 RNA sequencing experiment 
2.7.1 Specimen collection and laser capture microdissection (LCM) 
Four healthy rats and six rats bearing a malignant urothelium were anesthetized. Subsequently, 
rats were euthanized, the bladders were dissected, cut open and immediately embedded into 
Tissue Tek medium (Miles Inc, Elkart, IN, USA). The bladders were then snap-frozen in 
isopentane-cooled liquid nitrogen. Cryostat microtomy was performed to obtain 10 µm bladder 
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sections that were mounted onto DNAse- and RNAse-free PET-membrane-coated metal frame 
slides (1.4 µm, Leica). Immediately before performing LCM, the cryosections were stained with a 
standard H&E staining.  
Based on the H&E staining, healthy and malignant urothelial tissue was microdissected using a 
Leica DM60000B microscope (Leica Microsystems). The lasered fragments were captured on the 
cap of 200 µl PCR tubes (Greiner bio-one), filled with 25 µl RLT plus buffer (Qiagen) + 1% 2-
mercaptoethanol. After the microdissection, PCR tubes were closed, centrifuged for 30 sec and 
stored at -80 °C until further processing. For each rat, four cryosections were microdissected. An 
overview picture of a stained cryosection was taken with the Leica microscope. 
 
2.7.2 RNA extraction, quality control and sequencing 
Microdissected tissue from the same rats was pooled together, after which RNA was extracted 
according to the protocol described in the RNeasy plus microkit. RNA concentration and purity 
were determined spectrophotometrically using the Nanodrop ND-1000 (Nanodrop 
Technologies) and RNA integrity was assessed using a Bioanalyser 2100 (Agilent). Per sample, an 
amount of 1 ng of total RNA was used as input for the SMART-Seq v4 Ultra Low Input RNA 
protocol (version “040215”) from Clontech Laboratories Inc. Subsequently, 1 ng of purified 
cDNA was sheared to 300 bp using the Covaris M220. From the sheared material, sequencing 
libraries were prepared with the NEBNext Ultra DNA Library Prep Kit for Illumina (version 2.0 
-1/15), according to the manufacturer‟s protocol including a size selection to 250 bp insert size 
with the following minor modifications: only half of the library was subjected to a 15 cycle PCR 
in the final library amplification step. Sequence-libraries of each sample were finally equimolarly 
pooled and sequenced on ½ NextSeq500 flow-cell at 1x75 bp. 
 
2.7.3 Data analysis 
After cleaning and adapter removal, preprocessed reads were mapped to the Rattus norvegicus 
reference genome (rnor50) with Tophat v2.0.13. The number of reads in the alignment, 
overlapping with gene features, were counted using featureCounts 1.4.6 [13]. Subsequently, genes 
with less than 1 count-per-million were removed and normalization was performed for GC 
content, library size and RNA composition using EDASeq package from Bioconductor [14]. 
Principal component analysis (PCA) was carried out to identify expression patterns in the dataset. 
To obtain the differentially expressed genes between the two conditions, statistical comparative 
analysis was performed with EdgeR 3.4.0 (Bioconductor Package) [15]. The resulting p-values 
were corrected for multiple testing with Benjamini-Hochberg to control the false discovery rate 
(FDR) [16]. Results are given as log2 fold change and a FDR p-value below 0.05 was considered 
as significant. Genes with a log2-ratio < -1 and > 1 were considered as down- and up-regulated, 
respectively.  
Special interest was shown for genes related to cell adhesion. Cell adhesion genes were identified 
by means of a thorough literature search [17-19] and using the „Pathway Unification Database‟ 
website [20]. Following keywords were entered: „cell adhesion molecules‟, „tight junction‟, 
„adherens junction‟, „tight junction interactions‟ and „adherens junctions interactions‟. 
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2.7.4 Functional enrichment analysis 
In order to comprise the dataset into more biologically interpretable data, a functional 
enrichment analysis was performed. Since the rat‟s pathways are poorly annotated and most 
databases are made for human genes, the putative orthologous genes in human were extracted for 
the 14,115 genes annotated in the rat genome used for the statistical analysis. 10,740 orthologous 
genes were obtained using one-2-one orthologous relationship from Ensembl (BioMart Portal 
v0.9). The gene enrichment analysis was performed online with WebGestalt (WEB-based Gene 
SeT AnaLysis Toolkit) [21] using our sets of differentially expressed genes. The pathway analysis 
was performed using the annotated pathways of KEGG (Kyoto Encyclopedia of Genes and 
Genomes) database with default significance level of 0.05 (FDR corrected p-values). 
 
3. RESULTS 
3.1 Accumulation of EB in rat bladders and plasma after intravesical instillation 
3.1.1 Visual inspection of inner wall rat bladder 
Figure 3.1 shows representative pictures of the inner wall of rat bladders after instillations of 1 
mM EB for 2 hrs and 5 mM EB for 1 hr, as visualized by WL stereomicroscopy at low 
magnification. In healthy bladders instilled with the lowest concentration of EB, the blue staining 
is almost non-existent (3.1A), while a clear blue but non-homogeneous staining is visible in the 
tumor bladders (3.1B). Healthy bladders instilled with the highest concentration show some non-
specific blue staining (3.1C), the tumor bladders exhibit an intense blue color (3.1D). In both 
conditions, the healthy rat bladders are less stained when compared with the tumor conditions. 
 
 
Figure 3.1: Representative pictures of cut-open rat bladders 
Pictures of the inner wall of rat bladders after a 2 hrs instillation of 1 mM EB (A-B) and a 1 hr 
instillation of 5 mM EB (C-D) as visualized by WL stereomicroscopy. Figures A and C show 
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healthy rat bladders, figures B and D rat bladders with a malignant urothelium. Original 
magnification = 1.25x 
 
In order to compare the amount of EB present in healthy and malignant rat bladders after 
intravesical instillation, EB was extracted and quantified using a HPLC method. 
 
3.1.2 Validation of HPLC method 
Selectivity. The method for the chromatographic analysis of rat bladder samples and rat plasma 
samples showed no interference from endogenous components at the retention times of EB (2.0 
min) and IS (3.5 min). A typical chromatogram is given in Figure 3.2. 
 
 
Figure 3.2: Representative chromatogram showing peaks of EB and NBB 
Chromatogram of a plasma sample spiked with EB and NBB, final concentrations of 8 µg/ml 
and 7.5 µg/ml, respectively. EB = Evans blue, NBB = napthol blue black, the internal standard 
 
Linearity. The calibration curve of EB from standard solutions was linear over the concentration 
range of 0.25 to 16 µg/ml (n=3, rmean = 0.998). The mean equation of the 3 curves was the 
following: „y = 262321 x – 73868‟ with x = EB concentration and y = area under the curve. 
 
Recovery. The mean (± SD) recovery of EB from FCS was 77.4 ± 8.8 %. 
 
3.1.3 Determination of Evans blue in rat bladder homogenates after intravesical instillation 
Figure 3.3 compares quantitatively the concentration of EB in bladder homogenates after 
instillation of the compound in healthy rat bladders and in bladders with a malignant urothelium. 
The graph from Figure 3 indicates that in both conditions tested, more EB was taken up in the 
tumor bladders as compared to healthy bladders, though this difference was only found to be 
significant in the 1 mM-2hrs condition. On average, the concentration of EB in tumor bladder 
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homogenates was 5.5 times higher than in healthy bladder homogenates in the 1 mM-2hrs 
condition. In the 5 mM-1hr condition, a 3.2-fold increase could be observed. These findings 
match the observations of blue color in the bladder samples, as visualized in Figure 3.1. 
 
 
 
Figure 3.3: Concentration of EB in bladder homogenates after intravesical instillation 
The concentration of EB found in homogenates of healthy bladders (H) and bladders bearing 
tumors (T) after intravesical instillation is compared. Two conditions were tested: 1 mM 
instillation of EB for 2 hrs (A) and 5 mM instillation of EB for 1 hr (B) n = 5 for each condition. 
Means + SEM are shown.  * = p-value < 0.05. 
 
3.1.4 Determination of Evans blue in rat plasma after intravesical instillation 
To determine the amount of EB that evades from the bladder into the circulatory system, the 
concentration of EB in rat plasma was quantified after intravesical instillation in both healthy and 
malignant rat bladders. Determination of EB concentrations was also investigated 3 hrs after 
removal of the catheters to examine the retention of EB in rat blood. As Figure 3.4 shows, there 
were no significant differences in EB concentrations in plasma of normal rats compared to rats 
with a malignant urothelium after instillation of EB in all conditions tested (1 mM-2hrs-5hrs, 5 
mM-1hr-4hrs). As expected, a 5 mM instillation led to a higher concentration of EB in the 
plasma compared to a 1 mM instillation (3 to 4- fold increase). The highest mean concentration 
in rat plasma, 7 µg/ml, was observed for the 5 mM-1hr condition in healthy rat bladders. After a 
3 hrs EB instillation-free period, EB concentrations did not significantly change.  
  
Figure 3.4: Concentration of EB in bladder plasma after intravesical instillation 
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The concentration of EB found in rat plasma after intravesical instillation in healthy bladders (H) 
and bladders bearing tumors (T) is compared. Four conditions were tested: 1 mM EB instillation 
for 2 hrs (1mM-2h), 5 mM EB instillation for 1 hr (5mM-1h) and the blood samples taken 3 hrs 
after the end of instillation (1mM-5h and 5 mM-4h). n = 3 for each condition. Means + SEM are 
shown.  
 
3.2 Repeated intrabladder instillation of Evans blue 
EB solutions or PBS (control) were instilled for 7 consecutive days in normal rat bladders to 
examine possible adverse effects of EB on the bladder wall. In the control PBS samples (Figure 
3.5C), the urothelium appeared normal in all 3 rat bladders, while in 2 bladders a purulent 
inflammation was found in the muscularis. In the third rat, oedema was present in the lamina 
propria. The histological injuries seen in these control conditions are likely due to the repeated 
instillation procedure.  
A 7-day repeated instillation of 1 mM EB did not show any more signs of adverse effects 
observed within the bladder wall as compared to the control conditions (Figure 3.5A). Histologic 
analysis showed that the urothelium was normal in all cases. Slight inflammation and oedema was 
noticed in the lamina propria and 1 bladder showed a purulent inflammation in the muscularis. 
Also in case of the 5 mM EB instillations, the urothelium of the 3 rat bladders was normal 
(Figure 3.5B), while inflammation and oedema was noticed in the lamina propria and in the 
muscularis of 2 rats.  
 
 
Figure 3.5: Representative H&E stainings of 5-µm sections of rat bladders  
Photomicrographs of the H&E stained sections after a daily 1-hr instillation of EB or PBS for 7 
consecutive days. (A) 1 mM EB, (B) 5 mM EB, (C) PBS; Original magnification = 100x 
 
3.3 RNA sequencing experiment 
In order to better understand the differential accumulation of EB in urothelial tumor tissue 
versus healthy tissue, a RNA sequencing experiment was designed to specifically look at the gene 
expression of urothelial tissue. To isolate the urothelium, laser capture microdissection was 
performed. A picture of a rat bladder cryosection is given in Figure 3.6, in which the dotted line 
separates the urothelium (above) from the underlying layers (under).  
Chapter 3: Evans blue-mediated white-light detection of NMIBC: feasibility and safety study 
 
49 
  
 
 
3.3.1 Comparative analysis between tumor samples and healthy samples 
Principal component analysis demonstrated that one tumor sample did not cluster well with the 
other five tumor samples. This sample was therefore considered as an outlier and was left out of 
the comparative analysis. Comparative analysis of the remaining tumor samples and the four 
healthy samples showed that 2441 genes were down-regulated (log2-ratio < -1) and 2244 genes 
were up-regulated (log2-ratio > 1) in tumor vs. healthy samples (p < 0.05), as visualized by a 
Volcano plot (Figure 3.7). 
 
 
Figure 3.7: Volcano plot for tumor samples vs. healthy samples.  
The vertical lines correspond to a log2-fold change of -1 and 1, while the horizontal line indicates 
a p-value of 0.05. The dots are colored green or red if classified as down- or up-regulated, 
respectively. 
 
Since we hypothesized before that EB specifically accumulates in tumor tissue due to defects in 
the urothelial barrier [11], genes correlated to cell-cell adhesion were selected and the expression 
levels analyzed. The focus was set on genes belonging to or correlated to the three typical cell 
Figure 3.6: Picture of a healthy 
rat bladder cryosection after 
H&E staining. The dotted line 
separates the urothelium (above) 
from the underlying layers (under) 
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adhesion structures: tight junctions, adherens junctions and desmosomes. The results can be 
found in Table 3.1. This table clearly shows that many genes related to cell adhesion were 
differentially expressed in malignant urothelium compared with normal urothelium. When 
looking at genes related to tight junctions (TJs), 13 genes were found to be down-regulated, 8 
genes were up-regulated. These genes include 5 different kinds of claudins, the major building 
blocks of TJs. It is also clear that many of these genes were up- or down-regulated at a very high 
level, e.g. Cldn3 was 237-fold up-regulated, Cldn 23 was 110-fold down-regulated in tumor 
urothelium vs. normal urothelium, respectively. Also genes encoding proteins involved in 
adherens junctions (AJ) were differentially expressed, though at a lower level compared to the TJ-
related genes. Highest levels of up-regulation were seen for Cdh17 (18-fold), of down-regulation 
for Pvrl3 (13-fold). Three genes correlated to desmosomes were detected, e.g. Dsc2, Dsp and 
Pkp1. 
 
 
Table 3.1: Differential expression of cell adhesion genes in tumor samples vs. healthy 
samples. Down-regulated genes are indicated in green, up-regulated genes in red. Corrected p-
values were used, LogFC = the log2-ratio as calculated by EdgeR. 
 
 
 
 
3.3.2 Functional enrichment analysis 
To identify enriched pathways (PWs), our gene set was compared to predefined categories of the 
KEGG database. This analysis showed that the up-regulated differentially expressed genes were 
Tight junctions Adherens junctions Desmosomes
Gene ID LogFC p-value Gene ID LogFC p-value Gene ID LogFC p-value
Amotl1 -4,45 1,86E-07 Acp1 1,11 0,00527 Dsc2 1,99 4,13E-06
Cldn3 7,89 9,90E-39 Actb 3,00 3,51E-07 Dsp -1,64 0,00120
Cldn8 -6,78 3,00E-25 Actg1 2,55 0,00552 Pkp1 1,16 0,00179
Cldn11 -2,90 0,00956 Actn1 3,18 3,05E-07
Cldn18 3,85 0,00786 Actn4 1,32 1,42E-06
Cldn23 -5,07 2,14E-13 Baiap2 1,51 6,38E-06
F11r -1,22 7,62E-05 Cdh3 2,01 0,00576
Inadl -1,51 0,0238 Cdh4 -3,42 0,0187
Jam2 -2,99 0,00219 Cdh17 4,18 0,00247
Jam3 -2,35 0,0400 Cdh18 -2,97 0,0168
Magi3 -1,33 0,00173 Csnk2b -1,39 1,21E-07
Mpdz 2,74 0,00940 Ctnnd1 -1,26 0,00193
Pard6a 4,02 4,76E-05 Insr -1,90 0,0150
Pard6b 1,63 2,03E-05 Ptpn1 1,92 1,19E-06
Pard6g -4,48 1,13E-13 Ptprb -3,54 0,00075
Prkca 1,92 0,00302 Ptprf -1,41 4,90E-06
Prkch -1,97 0,00018 PVR 2,11 4,36E-11
Prkci -1,26 0,00011 Pvrl1 -3,13 0,00099
Prkcq -6,70 5,77E-13 Pvrl3 -3,68 0,00333
Rab3b 4,33 0,00065 Pvrl4 -2,43 9,39E-07
Ybx3 1,63 1,18E-06 Snai2 -2,76 0,00619
Was 4,01 0,00055
Wasl -1,17 9,02E-05
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related to 99 KEGG pathways (see supplemental Table S3.1). A top 10 of these up-regulated 
enriched PWs is given in Table 3.2. Notably, this table shows that the most significantly enriched 
PW is the cell cycle pathway. In relation to this PW, also DNA replication and MAPK signaling 
PWs are included in the top 10. Alongside this top 10, other interesting categories that were 
significantly enriched are the bladder cancer PW (R = 5.21, p = 0.0054), tight junction PW (R = 
3.34, p = 0.0025) and adherens junction PW (R = 3.62, p = 0.012). 
When analyzing the down-regulated differentially expressed genes, 53 different pathways were 
enriched (see Supplemental Table S3.1). The top 10 is shown in Table 3.2. Interestingly, many of 
the PWs in this top 10 are related to catabolism, in which the cells break down molecules into 
smaller units to release energy: lysosome PW, peroxisome PW and endocytosis PW are among 
this category. The PPAR signaling, terpenoid backbone synthesis, fatty acid metabolism and 
SNARE interactions in vesicular transport PWs also play an indirect role in the catabolic 
metabolism of the cells. Other interesting categories that were significantly enriched are the tight 
junction PW (R = 3.36, p = 0.0055) and the p53 signaling PW (R = 3.92, p = 0.017). 
 
Table 3.2: Top 10 enriched categories in the up- and down-regulated genes using the 
KEGG database. For each pathway, the number of genes found in that category as well as in 
our gene set is given, together with the total number of genes in that category. Also the ratio of 
enrichment and corrected p-values are shown. 
 
 
  
                     Top 10 enriched categories in the up-regulated genes
KEGG pathway
# differentially 
expressed genes
# genes in category
ratio of 
enrichment
p-value
Cell cycle 33 124 11,72 9,28E-24
Metabolic pathways 74 1130 2,88 4,76E-14
Small cell lung cancer 18 85 9,33 2,48E-11
DNA replication 13 36 15,91 2,48E-11
Pathways in cancer 33 326 4,46 3,46E-11
Focal adhesion 25 200 5,51 1,61E-10
Oocyte meiosis 19 122 7,47 2,10E-10
MAPK signaling pathway 27 268 4,44 2,55E-09
Regulation of actin cytoskeleton 24 213 4,96 2,55E-09
RNA transport 20 151 5,83 4,34E-09
                           Top 10 enriched categories in the down-regulated genes
KEGG pathway
# differentially 
expressed genes
# genes in category
ratio of 
enrichment
p-value
Metabolic pathways 92 1130 3,62 3,51E-23
Lysosome 18 121 6,61 2,06E-08
Valine, leucine & isoleucine degradation 11 44 11,10 1,39E-07
Peroxisome 12 79 6,75 7,65E-06
PPAR signaling 11 70 6,98 1,38E-05
Endocytosis 17 201 3,76 8,95E-05
Fatty acid metabolism 8 43 8,26 9,92E-05
Terpenoid backbone synthesis 5 15 14,81 2,00E-04
SNARE interactions in vesicular transport 7 36 8,64 2,00E-04
Glutathione metabolism 8 50 7,11 2,00E-04
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4. DISCUSSION 
Using a preclinical setting, we investigated in this study some practical aspects of the use of EB 
for future applications as a diagnostic dye in the detection of NMIBC in combination with WL 
cystoscopy. Besides, by performing transcriptome analysis of malignant and normal rat 
urothelium, we set out to mechanistically understand the accumulation of the compound in 
malignant bladder urothelium. 
Our results show that the total amount of EB accumulating in rat bladders bearing a malignant 
urothelium surpassed clearly the one found in healthy bladders, at least in case of a 1 mM EB 
instillation. The data therefore are in line with a previous study using an identical tumor model 
that quantified the fluorescence of EB at a microscopic level in the different layers of the bladder 
wall [11]. As a consequence, a differential uptake of EB in the malignant and normal inner 
bladder could also be observed by using WL stereomicroscopy. The previous study [11] showed 
as well that EB penetrates readily through the malignant urothelium reaching and afterwards 
accumulating in the deeper muscle layers, and hence the perpendicular stereomicoscopic view at 
the surface of the inner wall (as in case of a cystoscope) likely visualizes both. The images 
furthermore show a non-homogenous distribution of the blue color which probably reflects the 
variable proliferation of the AY-27 cells after inoculation, as observed before [11]. 
Although differences in accumulation of EB in tumor vs. healthy bladders were clear, this was 
not the case for the EB plasma levels. We expected to find less EB in the plasma of healthy rats 
due to the presence of a functional urothelial barrier as compared to the disrupted barrier in the 
rats bearing bladder tumors. However, it is possible that the catheterization procedure, also in 
control conditions, caused small injuries which enabled EB to penetrate into the blood stream 
without the need to pass through the urothelial barrier. Obviously this possibility should be 
investigated further using larger animals with bladders that are easier accessible.  
Approximately 5 % of the amount of EB instilled was able to pass into the blood stream in the 
conditions tested. Although this quantity might be an overestimation due to the specific 
instillation conditions used, the absorption across the bladder wall of EB into the blood stream 
could raise some safety concerns. At this point, it should be mentioned that EB has been 
frequently used as a dye marker to determine blood volume in humans [22-25]. To that end, EB 
is injected directly into the blood stream. Based on an average blood volume of 5 l for a person 
weighing 70 kg [26], the final concentration of EB inside the circulatory system in humans ranges 
between 6.36 µg EB/ml plasma [25] and 12.73 µg EB/ml plasma [23] after intravenous 
injections. These values are in the range of the highest mean concentration found in this study (7 
µg/ml). Moreover, Gibson & Gregerson [27] concluded that doses of EB up to 20 mg/kg are 
non-toxic when administered intravenously to growing rats. For a person of 70 kg, this dose 
would result in a plasma concentration of ca. 500 µg EB/ml plasma, which is a 70-fold higher 
than the highest mean concentration observed in our study. Other uses of EB in clinical practice 
include the detection of aspirated materials in patients with tracheostomy [28] and imaging in 
cardioscopy [29]. Overall, the widespread use of EB for different applications in the clinic seems 
to indicate that even when intravesically instilled EB leaks into the bloodstream, the safety risk 
for the patients is deemed very low.   
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Of particular interest, no adverse effects on the urothelium were found after a daily instillation of 
EB for 7 days, not even after intravesical application of concentrations of EB as high as 5 mM. 
Since the urothelium is directly exposed to the EB solutions, these data again point to the fact 
that the compound possesses a high non-toxic profile. This characteristic might be partially due 
to the fact that the compound is not likely to accumulate intracellularly as it features a high 
molecular mass (Mr: 960) in combination with four sulphonic substituents that are completely 
ionized at physiological pH. However, some inflammation was noticed in the other layers, e.g. 
lamina propria and muscularis, of some, but not all, rat bladder samples. Since these injuries were 
also present in the control bladders, we hypothesize that the inflammation observed was due to 
the repeated instillation procedure and not to adverse effects induced by EB itself.  
We previously assumed that EB selectively accumulates paracellularly in tumor tissue due to 
defects in the urothelial barrier [11]. To investigate this hypothesis into more detail, 
transcriptome analysis of the urothelium was performed and the differential expression between 
healthy and malignant urothelium was analyzed. It is clear from the data that many genes related 
to cell adhesion were differentially expressed, especially genes related to tight junctions. Also 
genes that are associated with adherens junctions and desmosomes were found to be significantly 
up- or down-regulated.  
A first important observation is the presence of 5 claudin genes, differentially expressed with 
high values. Claudin proteins are the most important components of TJs. A study investigating 
the expression of claudins in normal and neoplastic human tissues concluded that most claudin 
genes are decreased in tumors, except for CLDN3, CLDN4 and CLDN7, which are elevated in 
some kinds of cancer, including bladder cancer [30]. This conclusion matches our results, in 
which Cldn8, 11 and 23 were significantly down-regulated in malignant urothelium, while Cldn3 
was 237 times up-regulated. The AMOTL1 gene, coding for the junctional adhesion molecule A 
(JAM-A), is involved in the regulation of TJ development between epithelial cells. Different 
studies have indicated that down-regulation of this protein is linked to invasion, metastasis, poor 
prognosis and progression in pancreatic cancer [31], renal cell carcinoma [32] and breast cancer 
[33-34]. This correlates with the 22-fold down-regulation of the Amotl1 gene seen in our data set 
and highlights the high-grade character of our rat tumor model. Another gene of interest, down-
regulated 104-fold in tumor tissue in our data set, is the Prkcq gene, coding for protein kinase C θ 
protein. This protein plays a key role in the activation and survival of T-cells and is also required 
for effective anti-tumor immune surveillance in vivo [35], which would explain the lower 
expression in a tumor environment as a strategy to inhibit eradication by the host immune 
system. On the other hand, inhibition of this protein has been shown to maintain the integrity of 
TJs in cardiac endothelial cells [36], which is contradictory to our theory of decreased cell 
adhesion. However, since PRKCQ is involved in many processes, it is difficult to draw a clear 
conclusion in relation to its involvement in cell adhesion in our tumor model. PARD6G has a 
known tumor-suppressor function and is therefore often down-regulated or even deleted in 
epithelial cancers [37], which is also observed in our dataset. RAB3B is a member of the RAS 
oncogene family and is observed to be up-regulated in this study.  
When looking into more detail at the differentially expressed genes correlated to adherens 
junctions, four different cadherins and one catenin, the major building blocks of AJs [17], are 
noticed. The best studied cadherin is E-cadherin (CDH1), the most important mediator of cell-
cell adhesion in epithelial tissues and also an important tumor suppressor [38]. It is well 
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documented that, during the epithelial-to-mesenchymal transition (EMT), an important first step 
of cancer metastasis, a cadherin switch occurs. In different malignancies, it is observed that the 
expression of E-cadherin decreases, while the expression of N-cadherin (CDH2) and/or P-
cadherin (CDH3) increases [39]. In the case of bladder cancer, a transition to N-cadherin and P-
cadherin has also been observed, though the exact timing and combination of expression of the 
three cadherins remains to be elucidated [39]. When these studies are regarded in the light of our 
study, we can see that P-cadherin is indeed significantly up-regulated four times in tumor tissue as 
compared to healthy tissue, but the expression of E-cadherin and N-cadherin was not 
significantly different. This observation might be explained in two ways: it is possible that in our 
tumor model, the cadherin switch starts with an increased expression of P-cadherin and that a 
decreased E-cadherin expression starts later in the tumorigenesis. Another possibility is that the 
EMT has not started yet and that the P-cadherin expression should be regarded separately. Bryan 
et al [40] studied the expression of P-cadherin in vivo and concluded that even in the presence of 
normal E-cadherin expression, an increased expression of P-cadherin was associated with a more 
malignant phenotype of bladder cancer. The protein expression of E-cadherin in an identical 
animal model was previously investigated by our group by means of immunohistochemistry [11]. 
It was concluded that no differences in expression of E-cadherin were found, confirming the 
gene expression of the Cdh1 gene in this study. Two other proteins were investigated by Elsen et 
al [11]: claudin-1 and desmoglein-1. The Cld1 gene and Dsg1 were not differentially expressed in 
our gene analysis, but we did find a decreased expression of desmoglein-1 in malignant 
urothelium in the previous study [11].  
Interestingly, the enrichment analysis points to the involvement of cell adhesion as well: the tight 
junction PW was enriched in the up- as well as the down-regulated genes, the adherens junction 
PW in the up-regulated genes. The cell-cycle PW was the most significantly enriched PW coming 
out of the analysis, confirming the observations of different other authors investigating human 
bladder samples [41-43]. In the study of Shen et al [41], 256 human samples were analyzed, 
including healthy bladder mucosa, recurrent NMIBC and primary bladder tumors. KEGG 
enrichment analysis revealed 7 significantly enriched up-regulated PWs, 5 of which were also 
found in our study, and 47 significantly enriched down-regulated PWs, 8 of which recur in this 
study. Arum et al [44] performed PW analysis of bladder tumors, grown for 14 days in an AY-27 
rat bladder tumor model, and found 20 significantly enriched up-regulated KEGG PWs, 15 PWs 
recurring in our study. In none of the aforementioned studies the TJ or AJ pathways were 
observed in the enrichment analysis, though the pathway „cell adhesion molecules‟ was enriched 
in Arum et al [44]. However, in our study, RNA was specifically isolated from the urothelium, the 
outer layer which forms the barrier of the bladder wall and therefore the layer that will be altered 
in terms of cell adhesion. In the other studies, whole tumors (NMIBC or MIBC)/whole rat 
bladders were investigated, which might explain the absence of cell adhesion PWs in the 
enrichment analysis.  
Taken together, the data show that many genes involved in cell adhesion are differentially 
expressed in healthy and malignant urothelium, pointing strongly to defects in the urothelial 
barrier. Although the relative expression of genes does not necessarily reflect the abundance of 
the corresponding proteins, it is anticipated that also at the level of protein expression major 
defects are present. Indeed, our results are fully in line with the previously observed 
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ultrastructural defects, as malignant tissue displayed wider intercellular spaces and a decreased 
number of cell junction components compared with normal tissue [11].  
In conclusion, we have shown that EB is selectively taken up by tumor tissue after intravesical 
instillations in rats bearing bladder tumors compared with normal rats. EB instillations do not 
harm the bladder wall and penetration into the circulatory system is limited, especially when low 
concentrations are used. The selective uptake of EB is probably due to defects in the urothelial 
barrier, as shown by differential expression of cell adhesion genes and by pathway analysis.  
If these preclinical results on EB can be confirmed in a human setting, we believe that our 
findings can be important for future clinical developments in the field of diagnostics for bladder 
cancer. Implementing the cheaper protocol of EB instillations in combination with WL 
cystoscopy might offer a benefit for patients and society in comparison with the expensive 
photodynamic procedure.    
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SUPPLEMENTAL DATA 
Table S3.1: Enriched categories in the up- and down-regulated genes using the KEGG 
database
 
Enriched KEGG PWs for the up-regulated genes in 
order of significance
Enriched KEGG PWs for the down-regulated genes in 
order of significance
Cell cycle Metabolic pathways
Metabolic pathways Lysosome
Small cell lung cancer Valine, leucine & isoleucine degradation
DNA replication Peroxisome
Pathways in cancer PPAR signaling
Focal adhesion Endocytosis
Oocyte meiosis Fatty acid metabolism
MAPK signaling pathway Terpenoid backbone synthesis
Regulation of actin cytoskeleton SNARE interactions in vesicular transport
RNA transport Glutathione metabolism
Osteoclast differentiation Propanoate metabolism
Leukocyte transendothelial migration Biosynthesis of unsaturated fatty acids
Chemokine signaling pathway Protein processing in endoplasmic reticulum
Spliceosome Drug metabolism - cytochrome P450
Cytokine-cytokine receptor interaction Metabolism of xenobiotics by cytochrome P450
Leishmaniasis Tryptophan metabolism
Progesterone-mediated oocyte maturation Sphingolipid metabolism
p53 signaling pathway Steroid hormone biosynthesis
Pyrimidine metabolism TGF-beta signaling pathway
NOD-like receptor signaling pathway Fatty acid elongation in mitochondria
Chronic myeloid leukemia Steroid biosynthesis
Purine metabolism Tight junction
Protein processing in endoplasmic reticulum Cysteine and methionine metabolism
Glioma Insulin signaling pathway
Homologous recombination Circadian rhytm-mammal
Pancreatic cancer Basal cell carcinoma
Apoptosis Hedgehog signaling pathway
Hematopoietic cell lineage Inositol phosphate metabolism
Amoebiasis Phosphatidylinositol signaling system
Prostate cancer Melanogenesis
Neurotrophin signaling pathway Aldosterone-regulated sodium reabsorption
Jak-STAT signaling pathway Collecting duct acid secretion
Rheumatoid arthritis Pathways in cancer
T cell receptor signaling pathway p53 signaling pathway
Nucleotide excision repair Amino sugar and nucleotide sugar metabolism
Shigellosis Epithelial cell signaling in Helicobacter pylori infection
Ribosome biogenesis in eukaryotes Adipocytokine signaling pathway
Mismatch repair Fc gamma R-mediated phagocytosis
ECM-receptor interaction Other glycan degradation
Base excision repair Glyoxylate and dicarboxylate metabolism
Phagosome Calcium signaling pathway
Toxoplasmosis Pancreatic secretion
Arginine and proline metabolism Regulation of actin cytoskeleton
Adipocytokine signaling pathway Amoebiasis
Non-small cell lung cancer Pyruvate metabolism
Fc gamma R-mediated phagocytosis Retinol metabolism
Pathogenic Escherichia coli infection Proximal tubule bicarbonate reclamation
Galactose metabolism Glycolysis/Gluconeogenesis
Fc epsilon RI signaling pathway Salivary secretion
Toll-like receptor signaling pathway Lysine degradation
Colorectal cancer Vascular smooth muscle contraction
Proteasome Synthesis and degradation of ketone bodies
Chagas disease (American trypanosomiasis) Vasopressin-regulated water reabsorption
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Hypertrophic cardiomyopathy (HCM)
Glycolysis/Gluconeogenesis
Tight junction
Glutathione metabolism
Dilated cardiomyopathy
Malaria
Ubiquitin mediated proteolysis
Bacterial invasion of epithelial cells
Melanoma
Insulin signaling pathway
Vibrio cholerae infection
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
B cell receptor signaling pathway
Cytosolic DNA-sensing pathway
VEGF signaling pathway
Arachidonic acid metabolism
Glycerophospholipid metabolism
Endocytosis
Bladder cancer
Glycosphingolipid biosynthesis - lacto and neolacto series
TGF-beta signaling pathway
Natural killer cell mediated cytotoxicity
Glycosphingolipid biosynthesis - ganglio series
Complement and coagulation cascades
Viral myocarditis
RNA degradation
Glycerolipid metabolism
RIG-I-like receptor signaling pathway
Adherens junction
Amyotrophic lateral sclerosis (ALS)
Staphylococcus aureus infection
Acute myeloid leukemia
Hepatitis C
Nitrogen metabolism
ErbB signaling pathway
Protein export
Type I diabetes mellitus
Epithelial cell signaling in Helicobacter pylori infection
Renal cell carcinoma
Folate biosynthesis
RNA polymerase
Histidine metabolism
Axon guidance
Drug metabolism - other enzymes
Endometrial cancer
mTOR signaling pathway
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4.1 Evans blue as a new diagnostic tool for bladder cancer 
Treatment of bladder cancer (BC) remains a challenging problem for urologists. Urothelial cell 
carcinomas can be roughly divided into two groups: non-muscle-invasive-bladder cancers 
(NMIBC) and muscle-invasive bladder cancers (MIBC). Treatment options depend very strongly 
on the grade and stage of the cancer at initial diagnosis, with the majority of patients 
(approximately 75 %) presenting with NMIBC (Sharma et al, 2009). Although the 5-year survival 
rate for NMIBC is relatively high (>90%) (American Cancer Society, 2015), 30 to 80 % of 
patients experience a recurrence of the disease after initial treatment and up to 45 % of patients 
will develop invasive cancer within 5 years (van Rhijn et al, 2009). Therefore, patients require 
extensive follow-up, causing BC to have the highest lifetime treatment cost per patient of all 
cancers (Sievert et al, 2009). 
To minimize recurrences and progression, detection of tumors needs to be improved. The 
standard method to diagnose BC is white-light (WL) cystoscopy. In general, exophytic lesions are 
easily detectable using this technique, but small papillary lesions and especially flat carcinoma in 
situ (CIS), exhibiting a very malignant invasive character, are underdiagnosed. New imaging 
techniques have been developed with the aim to solve this problem: photodynamic diagnosis 
(PDD), narrow band imaging (NBI), optical coherence tomography (OCT) and very recently 
SPIES (Storz Professional Imaging Enhancement System). Despite these interesting 
developments, only the use of PDD has been implemented in the guidelines of the European 
Association of Urology (EAU) (EAU guidelines, 2015), but even so, the investment of specific, 
expensive equipment and the high costs of the instillation agent Hexvix®/Cysview® hampers 
the widespread use of PDD in clinical practice.  
Conversely, the use of a dye that specifically accumulates in or between tumor cells would be an 
ideal solution. The advantages of PDD could then be combined with the less expensive WL 
cystoscopy protocol. After in vitro investigating different compounds with high absorption 
coefficients in the visible light spectrum, Evans blue (EB) was selected as the only dye showing 
the desired tumoritropic characteristics as revealed with spheroids composed of malignant 
urothelial cells (Roelants et al, 2012). It was concluded that the compound is a possible promising 
tool as a clinical diagnostic for bladder cancer. The tumor-accumulating properties of EB have 
already been investigated before by other groups. By injecting EB intravenously in mice, the 
compound accumulated specifically in different kind of tumors (skin tumors, mammary, 
neurofibrosarcoma, ovarian carcinoma) (Moore et al, 1943; Maeda, 2012). The accumulation of 
EB in this type of tumors is due to the „enhanced permeability and retention‟ effect, a unique 
phenomenon of solid tumors (Fang et al, 2011). Basically, since tumor tissue is highly 
vascularized and large gaps are present between the endothelial cells, macromolecules are able to 
selectively accumulate in solid tumors. However, the use of EB as a marker for tumor tissue has 
never been investigated for superficial forms of bladder cancer. 
In this preclinical study, the possible use of EB as a diagnostic tool for bladder cancer was 
investigated using an in vivo orthotopic AY-27 rat bladder cancer model. This preclinical model, 
originally developed by Xiao et al (1999), consists of high-grade UCC tumors that invade the 
muscularis at some time point after inoculation. To obtain an intact and superficial non-muscle-
invasive bladder tumor, in our hands malignant AY-27 cells were allowed to grow for two days 
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after inoculation (Vandepitte et al, 2010). At this time point, pathological examination indicated 
that the tumors generated were high-grade carcinoma in situ. No invasion in underlying tissues 
was seen, the nuclei were enlarged, variable in size and arranged disorderly (anisokaryosis). Also a 
loss of polarization was noticed. Additionally, the green fluorescent cell tracker DiO 
demonstrated the superficial nature of the tumors generated. 
To evaluate the tumoritropic behavior of EB using the AY-27 rat model, two experiments were 
performed. First, the fluorescent properties of EB were used to quantify the accumulation of this 
compound in the different layers of the bladder wall (urothelium, submucosa, muscularis). Three 
conditions were tested: 1 mM EB instillation for 1 h and 2 hrs and 2.5 mM EB instillation for 1 
h. For the 1 mM concentrations, the accumulation of EB in tumor bladders was substantially 
higher compared with healthy bladders. When instilling 1 mM EB for 2 hrs, the fluorescence in 
malignant urothelium was found to be 55 times higher than in the healthy urothelium. This is a 
remarkable result, since in an identical rat tumor model, the fluorescence of the NMIBC-
diagnostic PVP-hypericin was only 3 to 4 times higher in malignant urothelium compared with 
the normal situation, while PpIX-related fluorescence after HAL instillations was even almost 
equal in normal and malignant tissue (Vandepitte et al, 2011). With a longer instillation time (2 
hrs), EB also accumulated in the muscle layer of the tumor bladders, which was not seen in the 
case of PVP-hypericin. The red fluorescence of EB correlated well with the green fluorescence of 
the tumor tracker DiO, except for the red fluorescence found in the deeper muscle layer.  
 
The future goal of this research is to apply EB in combination with WL cystoscopy without the 
need for fluorescence imaging. Therefore, in a second experiment we visually inspected by 
stereomicroscopy the level of staining of the inner bladder wall after intrabladder instillation of 
EB. Ideally, healthy rat bladder walls should not exhibit any blue appearance, whereas tumor 
walls should show a uniform blue coloring. However, especially in case of the highest EB 
concentration (5 mM), healthy rat bladders presented with spots with intense blue staining, an 
outcome that was also observed in case of the tumor-bearing bladders. Although the origin of 
these blue areas is not known and definitely deserves to be investigated further, it is possible that, 
due to inflammation or small injuries as a consequence of catheterization, some of the EB was 
able to locally penetrate into the bladder wall. In case of the tumor-inoculated bladders, in general 
a more intense blue color could be noticed as compared to the normal bladders. This difference 
was also investigated and confirmed by quantitative analysis after chemical extraction. The non-
uniform distribution of the dye observed in the malignant inner walls is possibly due to an equally 
non-uniform proliferation of the local AY-27 tumor cells in the bladder wall, as has been noticed 
before by the use of DiO-labelled tumor cells and fluorescence microscopic analysis of the inner 
bladder wall (see pictures in Chapter 2). Conversely, according to Vandepitte et al (2010), the 
inoculated AY-27 cells exist for up to only 1 to 3 days as an intact NMIBC after tumor cell 
inoculation, and it is also conceivable that normal urothelium locally regenerated and replaced the 
tumoral lesions, resulting in less EB accumulation. Future work will have to further investigate 
into detail the relationship between the local EB coloration and presence/thickness of malignant 
tissue of the inner bladder wall. This can be done for instance by taking small biopsies for further 
microscopic analysis from selected and color-predetermined zones of the inner bladder walls.  
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4.2 Safety of Evans blue instillations 
To investigate local adverse effects, EB was instilled in healthy rat bladders for up to 7 
consecutive days. Histologic analysis showed that the urothelium, the outer layer of the bladder 
wall, was completely intact in case of exposure to 1 mM and 5 mM concentrations of EB. In 
some of the rats, slight inflammation and oedema was noticed in the underlying layers, e.g. in the 
lamina propria and muscularis. Since this kind of inflammation was also present in the control rat 
bladders, we hypothesize that the inflammation was caused by the daily catheterizations and not 
by harmful effects of EB. In humans, long-term catheterization is often associated with a typical 
form of mucosal irritation, commonly referred to as polypoid cystitis (Norlén et al, 1988). 
Polypoid cystitis is characterized by a polypoid („resembling a polyp‟) urothelium of normal 
thickness, an oedematous lamina propria and inflammation. The mucosal irritation is probably 
caused by mechanical irritation and/or pressure exerted by the catheter (Norlén et al, 1988; Sun 
et al, 2011). Our histological observations of the bladder wall correlated well with the 
characteristics of polypoid cystitis (e.g. normal thickness of urothelium, oedema in the lamina 
propria, inflammation), thereby strengthening our hypothesis.  
As discussed in the introduction, EB has been frequently used as a marker for blood volume 
determinations. Using this method, EB was injected directly into the blood stream, reaching 
concentrations ranging between 6.36 µg EB/ml plasma (Farquhar et al, 2002) and 12.73 µg 
EB/ml plasma (Crooke & Morris, 1942) (See discussion Chapter 3). The concentrations found in 
rat plasma after intravesical instillations ranged between 1.3 and 2.3 µg EB/ml plasma and 4.6 
and 7 µg EB/ml plasma after instillations of 1 mM and 5 mM, respectively. In case of 1 mM 
instillations, the best condition in the tumor accumulation experiments, the concentrations found 
in rat plasma are thus lower compared to typical concentrations used for blood volume 
determinations in humans. Gibson and Gregersen (1935) concluded that in rats, IV injections up 
to 20 mg EB/kg body weight were non-toxic and did not slow the growth of the animals. This 
observation was later confirmed in monkeys. A single intravenous dose of below 25 mg EB/kg 
body weight was non-toxic and the animals exhibited a normal behavior during the observation 
period of five weeks (Malaowall & Fong, 1962). A dose of 25 mg EB/kg would lead to appr. 800 
µg EB/ml plasma in a rat weighing 160 g, thus exceeding by a 100-fold the highest 
concentrations found in this study (7 µg/ml). We can conclude that the concentrations found in 
rat plasma after intravesical instillations are much lower than the concentrations considered as 
„safe‟ after intravenous injection of EB.  
After an instillation-free period of 3 hrs, concentrations of EB had not significantly decreased in 
the plasma. This can be explained by the firm binding of EB to albumin in the blood stream after 
injection, causing a very slow elimination of the dye from the blood. According to the 
disappearance curves of EB in human and dog plasma (Gibson & Evans, 1937; Miller 1947), 80-
90 % of the original amount of dye is still detectable in the blood stream 3 hrs after an 
intravenous injection.  
Contradictory to our expectations, there were no differences in the concentrations of EB found 
in the plasma of rats with normal bladders and rats with tumor bladders after intravesical 
application, despite the clear difference of accumulation in the bladder tissues. It thus seems that 
Evans blue was able to reach the circulatory system in equal amounts, irrespective of the presence 
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of tumor cells. Interestingly, also HAL instillations in healthy bladders have been shown to reach 
the blood stream. In the study of Klem et al (2006), healthy volunteers were intravesically instilled 
with radioactively labeled HAL. Seven percent of the amount instilled could be retrieved in the 
blood stream. This percentage agrees very well with the 5 % obtained in this study. 
 
4.3 Mechanisms behind the selective accumulation of EB in tumor tissue 
Normal urothelium forms a tight barrier against different kinds of external factors: urine 
constituents, irritants, toxins etc. Therefore, the cells of this outer layer are very tightly 
interconnected by means of adhesion between the urothelial cells. In normal urothelium, 
different kinds of specialized junctions are present (see Figure 4.1), each composed of specific 
proteins. The tight junctions (TJs) are formed near the apical surface of epithelial cells. The major 
building blocks of TJs are claudins, occludins and ZO (zonula occludens) proteins. Adherens 
junctions (AJs) usually occur more basal than the TJs and are composed of cadherins and 
catenins. A third important type of junction is the desmosome. Desmosomes are localized most 
basally and are built from desmogleins, desmocollins and desmoplakins. The main function of 
TJs is to tightly link the cells together and act as a selective permeability barrier, thus regulating 
the paracellular permeability. AJs and desmosomes are mechanical linkers of epithelial cells 
(Alberts et al, 2002), but AJs also play an important role in the formation of TJs (Hartsock & 
Nelson, 2008). 
 
It was hypothesized before (Roelants et al, 2012) that abnormalities in cell adhesion might play an 
important role in the selective uptake of EB in spheroids composed of malignant urothelial cells. 
This hypothesis was explored into more detail in this study. EB, a highly hydrophilic compound, 
normally is not able to pass the urothelium via transcellular transport and prefers the paracellular 
route between the cells. In normal urothelium, cells are very tightly linked together through the 
presence of intact junctions and EB cannot penetrate. In tumor tissue, cells are more loosely 
Figure 4.1: Cell adhesion 
structures between epithelial 
cells (adopted from Jefferson et al, 
2004) 
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attached due to abnormalities in the cell adhesion structures. In this situation, EB is able to 
penetrate via the paracellular route. This „defect barrier‟ hypothesis is visualized in Figure 4.2. 
 
 
Figure 4.2: ‘Defect barrier’ hypothesis 
(A) Normal urothelial cells are tightly linked together. EB molecules cannot pass this barrier. 
(B) Tumor cells are characterized by defect cell adhesion structures, thereby enabling EB 
molecules to pass via the paracellular route. 
 
We have investigated this hypothesis thoroughly in three ways. First, transmission electron 
microscopy (TEM) was performed to obtain a detailed ultrastructural view of cell adhesion 
between the cells. It was clear that in normal urothelium, cells were very tightly connected and 
showed a normal presence of cell junctions. Malignant urothelium was characterized by loosely 
attached cells with wide intercellular spaces. Also, less cell adhesion structures were present 
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between the tumor cells. Secondly, immunohistochemistry was performed to investigate the 
expression of three key constituents of TJs, AJs and desmosomes. Only desmoglein-1, 
component of desmosomes, was differentially expressed with a higher staining of the membranes 
in normal urothelium compared with malignant urothelium. Thirdly, gene expression analysis of 
malignant and urothelial tissue demonstrated that many genes related to components of the 
junctional complex were differentially expressed. Of particular interest, genes coding for proteins 
involved in TJ formation and regulation were differentially up- or down-regulated at a very high 
level. Since TJs are the structures responsible for regulating the permeability of the urothelium, 
this observation is in line with our observations that show an increased EB uptake. An important 
remark is that gene expression does not necessarily reflect protein expression. Nevertheless, this 
analysis on the gene level forms a good indication of the proteins that might play a role in cell-cell 
adhesion and might provide a guide to select the proteins that can be investigated 
immunohistochemically. Most importantly, also the pathway analysis supports the involvement of 
cell adhesion since the categories „tight junction PW‟ and „adherens junction PW‟ were 
significantly enriched. 
Taken together, these experiments indicated that cell adhesion is definitely impaired between the 
tumor cells in our rat model, thereby confirming our hypothesis of the defect urothelial barrier 
and the corresponding uptake of EB. Also in the human situation, cell adhesion seems to be 
abnormal in bladder tumors. Most research on this subject focusses on the epithelial-to-
mesenchymal (EMT) transition, an important hallmark of tumor progression and metastasis 
(Kalluri & Weinberg, 2009), and the related changes in cell adhesion molecules. The most 
important players in the EMT are three cadherins: E-cadherin, P-cadherin and N-cadherin. 
Simply stated, a switch from E-cadherin expression to P- and/or N-cadherin occurs during the 
EMT (Bryan & Tselepis, 2010). E-cadherin was not differentially expressed in our study, neither 
at the gene nor at the protein level. Gene expression of P-cadherin on the other hand was up-
regulated in tumor tissue and might indicate the first step in cadherin switching before EMT has 
actually taken place. However, in our study, the role of AJs seems to be less crucial than the role 
of TJs. Few studies have been performed on the subject of TJs in bladder cancer. Two studies 
indicate that loss of TJ structure leads to invasion and eventually to metastasis of bladder cancer 
(Martin et al, 2011; Martin & Jiang 2009). Claudin genes are typically down-regulated in malignant 
tissue, except for CLDN3, CLDN4 and CLDN7, which are found to be increased in human 
bladder tumor specimens (Hewitt et al, 2006). These findings are consistent with our results. 
The changes observed in the expression of genes encoding TJ proteins are not only specific for 
bladder cancer cells, but occur in a wide variety of epithelial-derived cancers, including pancreatic, 
colon, lung, ovarian, thyroid, prostate, esophageal and breast cancers (Ding et al, 2013). 
Overexpression or down-regulation of claudins is frequently observed, although the exact 
functions of these claudins and the timing of up- or down-regulations remain to be elucidated. 
Also the expression of genes and the proteins involved in AJ formation are found to be up- or 
down-regulated in different kind of epithelial cancers, though the timing is variable in different 
kind of cancers. For example, loss of E-cadherin expression in lobular breast cancers and diffuse-
type gastric cancer occurs very early in the tumorigenesis, while this decrease is only observed in 
late high-grade invasive tumors for prostate cancer, non-small cell lung carcinoma, colon cancer 
and ductal breast carcinoma (Vasioukhin, 2012). Up-regulation of P-cadherin is less studied. 
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Nevertheless overexpression of this protein has been observed for breast, colon, pancreatic, 
stomach and ovarian carcinoma (Bryan & Tselepis, 2010). Both TJ and AJ proteins seem to play 
an important role in the tumorigenesis of epithelial cancers. However, the interaction between 
those two kinds of junctions in cancer has not been extensively studied. It is known that the 
formation of AJs facilitates the assembly of TJs (Niessen, 2007), but more research is necessary 
to unravel the exact interplay between AJ and TJ proteins in cancer development. 
As mentioned before (section 4.1), EB has also been shown to be tumoritropic in solid tumors 
after intravenous (IV) injections. The mechanisms behind this kind of accumulation are partially 
similar to the situation of superficial bladder cancer cells, partially not. After IV injection of EB, 
this compound binds firmly to the plasma protein albumin. When reaching tumor tissue, the EB-
albumin complex (molecular weight of 68 kDa) is able to leak out of the blood stream into the 
tumor cells due to the large gaps present in the tumor vasculature. Once out of the circulatory 
system, EB-albumin accumulates in the interstitial space of the tumor tissue where it is retained 
for a long time (up to several weeks) (Maeda, 2012). This phenomenon, called the „enhanced 
permeability and retention‟ effect in solid tumors, is not specific for EB but is also true for 
molecules or particles with a molecular weight larger than 40 kDa. Therefore, it has been 
extensively studied as a means to deliver drugs in tumor tissue (Fang et al, 2011). We can 
consider the situation in the bladder, where the EB solution is delivered directly in contact with 
the tumor cells, as similar to the situation in solid tumors once EB-albumin has leaked out of the 
vasculature. Also in solid tumors the cells are less adhered to each other compared to normal 
cells (Cooper, 2000), which enables the EB-albumin complex to penetrate in the interstitial space 
between the tumor cells. An important difference is the fact that in the case of accumulation in 
solid tumors after IV injections, EB is firmly bound to albumin, while in case of intravesical 
instillations, EB is administered as a solitary compound. However, in both cases it is clear that 
EB, whether bound to albumin or not, is only able to accumulate between the cells and not 
intracellularly. Due to its highly hydrophilic character, solitary EB cannot be taken up by living 
cells (personal observations) and is even known as a dye exclusion marker to assess cell viability 
in plant protoplasts (Huang et al, 1986). After incubation with an EB solution, dead/dying cells 
will stain blue, while healthy protoplasts remain unstained.  
4.4 Translation of our findings into clinical practice 
Summing up, the results of our study indicate that EB might have great potential as a diagnostic 
tool for bladder cancer. Before being tested in clinical trials, it would be interesting to test EB 
instillations in combination with WL cystoscopy in an animal model. Only few studies have ever 
been published on the subject of using cystoscopy in rat models (Hendricksen et al, 2007; Bolenz 
et al, 2007). Since a specialized mini-endoscope, connected to an imaging device is needed for 
this kind of experiments, cystoscopy in rats is not a technique that can be standardly used. Also, 
in order to interpret cystoscopy results correctly, it is necessary to have some experience in 
endoscopic imaging, which makes this technique unsuitable for researchers without a proper 
clinical background. However, performing cystoscopy in living rats would have some advantages 
in the light of our study. By instilling EB and monitoring the blue staining of tumor cells in living 
animals, there is no need to sacrifice them in order to quantify the blue staining. The 
accumulation of EB in different stages of tumor growth could be evaluated in the same animal 
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and most importantly, evaluation of EB as a means of diagnosing bladder cancer could be 
assessed exactly as is done in humans. 
An optimal concentration and duration of EB instillations in humans will need to be found that 
results in a bright blue staining of tumor tissue without a non-specific blue staining of normal 
tissue. The best condition in our rat model was a 1 mM EB instillation for 2 hrs. Higher 
concentrations led to a higher non-specific blue staining. The 1 mM-2 hrs condition could be 
used as a starting point to optimize instillation conditions in humans. In fact, optimal instillation 
concentrations tested in a rat model correlated well with the optimal concentration in humans in 
the case of HAL. El Khatib et al (2004) investigated different concentrations of this compound 
in a rat tumor model. In that study, an 8 mM HAL instillation was one of the best concentrations 
in terms of fluorescence intensity. This result is consistent with the concentration that is 
nowadays applied in clinical practice for HAL instillations (BCFI, 2012). Therefore, we expect 
that the optimal instillation condition in our study is indicative of the right conditions in humans. 
Finally, if the positive results on EB in our study can be repeated in a human setting, we expect 
substantial benefits by implementing the EB protocol combined with WL cystoscopy, not only 
concerning patient care but also in terms of economic costs. Given the widespread use of EB for 
different clinical applications, a future application of EB in diagnosing bladder cancer should be 
feasible. 
 
4.5 Future perspectives on the use of EB for other urinary bladder diseases 
In this thesis manuscript we have found some evidence of paracellular accumulation of EB in 
malignant urothelial tissue after intravesical instillations. This accumulation is probably due to 
defects in the urothelium barrier as extensively discussed in section 4.3. Hence other bladder 
pathologies showing similar urothelial barrier defects, e.g. interstitial cystitis/ painful bladder 
syndrome (IC/PBS), could potentially also be diagnosed using Evans blue WL cystoscopy. 
IC/PBS is a chronic and debilitating bladder disease characterized by urgency, nocturia and 
bladder pain. The estimated prevalence of IC ranges from 18 to over 400 cases per 100,000 
individuals, with a predominance of cases found in women (Persu et al, 2010). The etiology of 
IC/PBS is unknown. However, it is clear that the barrier function of the bladder is at least 
partially impaired, exposing the suburothelial nerve endings to toxic urinary compounds that 
cause pain (Cervigni, 2015). Currently, there is no single diagnostic gold standard and the 
diagnosis is based on a review of clinical symptoms, exclusion criteria and by cystoscopy and 
hydrodistention of the bladder under anesthesia. Obviously, a new diagnostic tool that is 
minimally invasive and that does not require anesthesia, would be highly appreciated.  
Possibilities to investigate EB instillations in preclinical models include the use of mice or rats in 
which IC/PBS is induced by administration of cyclophosphamide (Boudes et al, 2013). Another 
possibility is to work with a spontaneous IC/PBS model. Feline interstitial cystitis is a naturally 
occurring disease in cats, which reproduces many features of IC/PBS in humans diagnosed with 
this disorder and phenocopies much better the human disease than the available models of 
induced bladder injuries (Westropp & Buffington, 2002). 
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